{"content":"<li class=\"n-box-item date-title\" data-end=\"1515473999\" data-start=\"1515387600\" data-txt=\"Monday, December 23, 2019\">Monday, January  8, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3321762\" data-ts=\"1515456382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ILMN\" target=\"_blank\">ILMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321762-kingmed-diagnostics-to-buy-10_6m-in-equipment-from-illumina\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KingMed Diagnostics to buy $10.6M in equipment from Illumina</a></h4><ul>   <li>KingMed Diagnostics, a partner to Illumina (NASDAQ:<a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a>) on seeking Chinese approval for next-gen sequencing technology for disease testing, says it has agreed to buy at least $10.6M worth of medical devices from Illumina.</li>    <li>The news came in a statement to the Shanghai Stock Exchange.</li>    <li>Illumina shares, which <font color='red'>lost 0.5%</font> during the regular session, are <font color='green'>up 1.3%</font> after hours.</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321762\" data-linked=\"KingMed Diagnostics to buy $10.6M in equipment from Illumina\" data-tweet=\"$ILMN - KingMed Diagnostics to buy $10.6M in equipment from Illumina https://seekingalpha.com/news/3321762-kingmed-diagnostics-to-buy-10_6m-in-equipment-from-illumina?source=tweet\" data-url=\"https://seekingalpha.com/news/3321762-kingmed-diagnostics-to-buy-10_6m-in-equipment-from-illumina\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321760\" data-ts=\"1515454002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATCEY\" target=\"_blank\">ATCEY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321760-altice-spinning-off-67-interest-in-u-s-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altice spinning off its 67% interest in U.S. unit</a></h4><ul>   <li>Dutch cable/telecom giant Altice (<a href='https://seekingalpha.com/symbol/ATCEY' title='ALTICE S A ADR'>OTCPK:ATCEY</a>) will spin off its two-thirds-plus stake in Altice USA (NYSE:<a href='https://seekingalpha.com/symbol/ATUS' title='Altice USA'>ATUS</a>) by the end of Q2, <a href=\"https://seekingalpha.com/filing/3826758\" target=\"_blank\">according to filings</a>.</li>    <li>And the Altice USA board has authorized a share buyback program of up to $2B.</li>    <li>Shares in Altice USA are <font color='green'>up 1.9%</font> after hours.</li>    <li>Altice will spin out its 67.2% interest on that timetable, and its chief Patrick Drahi will serve as board president for Altice Europe and chairman of the board for Altice USA.</li>    <li>\"Altice N.V. believes the proposed separation of Altice N.V. and Altice USA through the Distribution will unlock the full value of Altice USA and allow Altice N.V. management to effect a turnaround of its French business more expeditiously,\" the filing says.</li>    <li>\"In addition, the Distribution and resulting separation of Altice N.V. and Altice USA will help Altice N.V. and Altice USA focus on their core businesses.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321760\" data-linked=\"Altice spinning off its 67% interest in U.S. unit\" data-tweet=\"$ATCEY $ATCEY $ATUS - Altice spinning off its 67% interest in U.S. unit https://seekingalpha.com/news/3321760-altice-spinning-off-67-interest-in-u-s-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3321760-altice-spinning-off-67-interest-in-u-s-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321757\" data-ts=\"1515450909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321757-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/SHLM' title='A. Schulman, Inc.'>SHLM</a> <font color='green'>+5.3%</font>. <a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a> <font color='green'>+4.2%</font>. <a href='https://seekingalpha.com/symbol/FSIC-OLD' title='FS Investment Corporation'>FSIC-OLD</a> <font color='green'>+1.3%</font>. <a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='green'>+1.3%</font>. <a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a> <font color='green'>+1.2%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/BGFV' title='Big 5 Sporting Goods Corporation'>BGFV</a> <font color='red'>-17.2%</font>. <a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='red'>-6.9%</font>. <a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty'>ELF</a> <font color='red'>-6.6%</font>. <a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a> <font color='red'>-2.5%</font>. <a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a> <font color='red'>-2.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321757\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$SHLM $ADMS $FSIC-OLD - After Hours Gainers / Losers https://seekingalpha.com/news/3321757-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3321757-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321756\" data-ts=\"1515450237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGFV\" target=\"_blank\">BGFV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321756-big-5-sporting-goods-lowers-q4-guidance-sharesminus-17-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big 5 Sporting Goods lowers Q4 guidance; shares -17% AH</a></h4><ul>     <li>Big 5 Sporting Goods Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/BGFV' title='Big 5 Sporting Goods Corporation'>BGFV</a>) now expects to realize a loss in Q4 in the range of ($0.08) - ($0.13) vs. a consensus of $0.25 and prior guidance of $0.16 - $0.28.</li>     <li>Net sales in Q4 were $243.2M (-8.7% Y/Y) vs. a consensus of $263.4M.</li>     <li>The Company expects to adjust its deferred tax assets based on the recent tax legislation and believes this will result in a one-time non-cash expense of ~$5.0M to $6.0M ($0.25 to $0.30/share) in the Q4.</li>     <li>Same store sales decreased 9.4% in Q4.</li>     <li>The Company&rsquo;s merchandise margins decreased ~130 basis points for the Q4.</li>     <li>For the FY17, the Company currently expects to realize EPS in the range of $0.52 - $0.57 vs. a consensus of $0.89.</li>     <li>CEO Steven G. Miller: \"Our disappointing fourth quarter performance was largely the result of an extraordinarily challenging December period\".</li>     <li>The Company expects to issue earnings results for the fiscal 2017 fourth quarter and full year by the end of February.</li><li>Shares&nbsp;<font color='red'>-17% AH</font></li><li><a href=\"https://seekingalpha.com/pr/17040993-big-5-sporting-goods-corporation-announces-fiscal-2017-fourth-quarter-full-year-sales-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3321756\" data-linked=\"Big 5 Sporting Goods lowers Q4 guidance; shares -17% AH\" data-tweet=\"$BGFV - Big 5 Sporting Goods lowers Q4 guidance; shares -17% AH https://seekingalpha.com/news/3321756-big-5-sporting-goods-lowers-q4-guidance-sharesminus-17-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/3321756-big-5-sporting-goods-lowers-q4-guidance-sharesminus-17-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321753\" data-ts=\"1515448428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321753-roku-says-active-accounts-hit-19m-shares-gain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku says active accounts have hit 19M; shares gain</a></h4><ul>   <li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) is <font color='green'>up 1.3%</font> after hours following an <a href=\"https://seekingalpha.com/filing/3826227\" target=\"_blank\">SEC filing</a> where it's disclosing that active accounts passed the 19M mark as of Dec. 31.</li>    <li>That number represents distinct users that have streamed any content on the platform within the past 30 days.</li>    <li>Shares <font color='green'>gained 2.6%</font> during the regular market session today; the company suffered a <a href=\"https://seekingalpha.com/news/3321367-roku-suffers-2nd-downgrade-2-days\" target=\"_blank\">pair of downgrades</a> last week from firms touchy about valuation (shares are <font color='green'>up more than 148%</font> over the past two months).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321753\" data-linked=\"Roku says active accounts have hit 19M; shares gain\" data-tweet=\"$ROKU - Roku says active accounts have hit 19M; shares gain https://seekingalpha.com/news/3321753-roku-says-active-accounts-hit-19m-shares-gain?source=tweet\" data-url=\"https://seekingalpha.com/news/3321753-roku-says-active-accounts-hit-19m-shares-gain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321749\" data-ts=\"1515447981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFM\" target=\"_blank\">SFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321749-sprouts-farmers-market-updates-guidance-ahead-of-icr-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprouts Farmers Market updates guidance ahead of ICR talk</a></h4><ul>     <li>Sprouts Farmers Market (NASDAQ:<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a>) updates on sales ahead of its presentation at the ICR Conference.</li>     <li>The company says Q4 comparable store sales increased 4.6%.</li>     <li>\"We are pleased to report that our strong performance continues, a direct result of our unique model offering health and value across the store, consistent execution and focus against our strategic initiatives,\" says Sprouts CEO&nbsp;Amin Maredia.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/17041086-sprouts-farmers-market-inc-announces-preliminary-fourth-quarter-2017-results\" target=\"_blank\">Press Release</a></li><li><a href=\"https://seekingalpha.com/news/search?query=%23ICR18\" target=\"_blank\">#ICR18</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3321749\" data-linked=\"Sprouts Farmers Market updates guidance ahead of ICR talk\" data-tweet=\"$SFM - Sprouts Farmers Market updates guidance ahead of ICR talk https://seekingalpha.com/news/3321749-sprouts-farmers-market-updates-guidance-ahead-of-icr-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3321749-sprouts-farmers-market-updates-guidance-ahead-of-icr-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321747\" data-ts=\"1515447627\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321747-urban-outfitters-slumps-after-holiday-sales-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urban Outfitters slumps after holiday sales update</a></h4><ul>     <li>Urban Outfitters (NASDAQ:<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a>) trades lower after posting holiday sales numbers below estimates.</li>     <li>The company says total sales were up <a href=\"http://investor.urbn.com/financial-news-%26-events/press-releases\" target=\"_blank\">3.6%</a> for the two-month period ending December 30, while comparable retail segment sales increased 2%.</li><li>Shares of URBN are&nbsp;<font color='red'>down 11%</font>&nbsp;in AH trading.</li><li><a href=\"https://seekingalpha.com/news/search?query=%23ICR18\" target=\"_blank\">#ICR18</a></li>      </ul><div class=\"tiny-share-widget\" data-id=\"3321747\" data-linked=\"Urban Outfitters slumps after holiday sales update\" data-tweet=\"$URBN - Urban Outfitters slumps after holiday sales update https://seekingalpha.com/news/3321747-urban-outfitters-slumps-after-holiday-sales-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3321747-urban-outfitters-slumps-after-holiday-sales-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321731\" data-ts=\"1515446443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STX\" target=\"_blank\">STX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321731-seagate-releases-preliminary-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seagate releases preliminary Q2 results</a></h4><ul><li>        Seagate Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a>) <a href=\"https://seekingalpha.com/pr/17041000-seagate-technology-announces-preliminary-financial-information-fiscal-second-quarter-2018\" target=\"_blank\">announces</a> preliminary financial results for Q2 with expected revenue of $2.9B (consensus: $2.74B) and gross margin of 30%.</li><li>               Operating expenses should come in around $444M GAAP and $390M non-GAAP. Seagate ended the quarter with $2.6B in cash and equivalents.&nbsp;</li><li>               Seagate expects to record 88 exabyte shipments with about 40M drive shipments and an average capacity per drive of 2.2TB.&nbsp;</li><li>                  Seagate will report Q2 results on January 29.    </li><li>               Seagate shares are<font color='green'>&nbsp;</font><font color='green'>up 3.9%</font>&nbsp;aftermarket. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321643-seagate-technology-plus-9_2-percent-cryptocurrency-connection\" target=\"_blank\">Seagate Technology +9.2% on cryptocurrency connection</a> (Jan. 8)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321717-analysts-put-seagates-crypto-stake-2-percent-3-percent\" target=\"_blank\">Analysts put Seagate's crypto stake at 2% to 3%</a> (Jan. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321731\" data-linked=\"Seagate releases preliminary Q2 results\" data-tweet=\"$STX - Seagate releases preliminary Q2 results https://seekingalpha.com/news/3321731-seagate-releases-preliminary-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3321731-seagate-releases-preliminary-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321724\" data-ts=\"1515445415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LUK-OLD\" target=\"_blank\">LUK-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321724-leucadia-mulling-sale-of-national-beef-packing-dj\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leucadia mulling sale of National Beef Packing - DJ</a></h4><ul><li>It's just a headline for now, but it was enough to send Leucadia (NYSE:<a href='https://seekingalpha.com/symbol/LUK-OLD' title='Leucadia National Corporation'>LUK-OLD</a>) from flat to&nbsp;<font color='green'>up 1.35%</font>&nbsp;in the last few minutes of the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321724\" data-linked=\"Leucadia mulling sale of National Beef Packing - DJ\" data-tweet=\"$LUK-OLD - Leucadia mulling sale of National Beef Packing - DJ https://seekingalpha.com/news/3321724-leucadia-mulling-sale-of-national-beef-packing-dj?source=tweet\" data-url=\"https://seekingalpha.com/news/3321724-leucadia-mulling-sale-of-national-beef-packing-dj\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321717\" data-ts=\"1515442914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STX\" target=\"_blank\">STX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321717-analysts-put-seagates-crypto-stake-2-to-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts put Seagate&#39;s crypto stake at 2% to 3%</a></h4><ul><li>        RBC Capital analyst Amit Daryanani <a href=\"https://www.cnbc.com/2018/01/08/wall-street-analysts-estimate-seagates-stake-in-ripple-company.html\" target=\"_blank\">says</a> Seagate Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a>) has a 2% to 3% stake in cryptocurrency company Ripple.</li><li>               Daryanani&rsquo;s estimate comes from management discussions, but the analyst thinks &ldquo;any indirect cryptocurrency ownership should be discounted somewhat due to inherent volatility and liquidity concerns.&rdquo;&nbsp;</li><li>               Susquehanna gave its clients a 2% to 4% ownership estimate for Seagate and said that, while the investment &ldquo;is intriguing, it&rsquo;s not a material upside driver since it&rsquo;s an equity investment, not a liquid cash source.&nbsp;</li><li>               Seagate shares are&nbsp;<font color='green'>up 7%</font>. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321643-seagate-technology-plus-9_2-percent-cryptocurrency-connection\" target=\"_blank\">Seagate Technology +9.2% on cryptocurrency connection</a> (Jan. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321717\" data-linked=\"Analysts put Seagate&#39;s crypto stake at 2% to 3%\" data-tweet=\"$STX - Analysts put Seagate&#39;s crypto stake at 2% to 3% https://seekingalpha.com/news/3321717-analysts-put-seagates-crypto-stake-2-to-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3321717-analysts-put-seagates-crypto-stake-2-to-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321716\" data-ts=\"1515442826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321716-fda-accepts-ionis-pharmas-marketing-application-for-inotersen-for-hattr-action-date-july-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Ionis Pharma&#39;s marketing application for inotersen for hATTR, action date July 6; shares up 4%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17039780-ionis-inotersen-nda-accepted-priority-review-fda\" target=\"_blank\">accepts </a>under Priority Review Ionis Pharmaceutical's (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='green'>+4.3%</font>) New Drug Application seeking approval for inotersen for the treatment of hereditary TTR amyloidosis (hATTR). The agency's action date is July 6.</li><li>Inotersen is an antisense drug designed to reduce the production of a protein called <a href=\"https://en.wikipedia.org/wiki/Transthyretin\" target=\"_blank\">transthyretin </a>which is misfolded and forms aggregates in amyloid disorders.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317722-alnylam-completes-u-s-marketing-application-patisiran-hattr-amyloidosis\" target=\"_blank\">Alnylam completes U.S. marketing application for patisiran for hATTR amyloidosis</a> (Dec. 12, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321716\" data-linked=\"FDA accepts Ionis Pharma&#39;s marketing application for inotersen for hATTR, action date July 6; shares up 4%\" data-tweet=\"$IONS - FDA accepts Ionis Pharma&#39;s marketing application for inotersen for hATTR, action date July 6; shares up 4% https://seekingalpha.com/news/3321716-fda-accepts-ionis-pharmas-marketing-application-for-inotersen-for-hattr-action-date-july-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3321716-fda-accepts-ionis-pharmas-marketing-application-for-inotersen-for-hattr-action-date-july-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321715\" data-ts=\"1515442451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321715-strong-move-up-for-tesla\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strong move up for Tesla</a></h4><ul> <li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) is <font color='green'>up 5.77%</font> and trades at its highest level of 2018 as investor sentiment bounces back strongly after last week's Model 3 deliveries update.</li> <li>Baird's Ben Kallo says the new production targets set on the Model 3 are bringing in new investors looking at the long-term potential and the \"de-risking\" of Tesla missing short-term delivery numbers.</li> <li>Kallo and team stick with an Outperform rating and <a href=\"https://www.streetinsider.com/Analyst+Comments/Tesla+%28TSLA%29+Shift+of+Targets+for+Model+3+Somwhat+De-Risked+-+Baird/13665701.html\" target=\"_blank\">$411 price target</a> on Tesla and show renewed confidence that the 5K per production rate is achievable without a capital raise from the EV juggernaut.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321715\" data-linked=\"Strong move up for Tesla\" data-tweet=\"$TSLA - Strong move up for Tesla https://seekingalpha.com/news/3321715-strong-move-up-for-tesla?source=tweet\" data-url=\"https://seekingalpha.com/news/3321715-strong-move-up-for-tesla\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>181&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321713\" data-ts=\"1515441609\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321713-restaurant-sector-jittery-icr-updates-roll-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Restaurant sector jittery as ICR updates roll in</a></h4><ul>     <li>The vibe in the restaurant sector is negative after full-year revenue and net income guidance from Dave &amp; Buster's Entertainment (<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color='red'>-21.8%</font>) disappointed earlier today</li>        <li>The jittery trading on traffic concerns is hitting BJ'S Restaurants (<a href='https://seekingalpha.com/symbol/BJRI' title='BJ&#39;s Restaurants, Inc.'>BJRI</a> <font color='red'>-5.4%</font>), Brinker International (<a href='https://seekingalpha.com/symbol/EAT' title='Brinker International, Inc.'>EAT</a> <font color='red'>-3.9%</font>), Sonic (<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a> <font color='red'>-2.4%</font>), Bojangles (<a href='https://seekingalpha.com/symbol/BOJA' title='Bojangles&#39;'>BOJA</a> <font color='red'>-3%</font>), Zoe's Kitchen (<a href='https://seekingalpha.com/symbol/ZOES' title='Zoe&#39;s Kitchen'>ZOES</a> <font color='red'>-2.4%</font>), Cheesecake Factory (<a href='https://seekingalpha.com/symbol/CAKE' title='The Cheesecake Factory Incorporated'>CAKE</a> <font color='red'>-2.9%</font>) and Del Frisco's Restaurants (<a href='https://seekingalpha.com/symbol/DFRG' title='Del Frisco&#39;s Restaurant Group'>DFRG</a> <font color='red'>-2.3%</font>).</li><li>The ICR Conference in Orlando this week is expected to give investors a better sense of what to expect in 2018.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3321608-weak-guidance-sends-dave-and-busters-reeling\" target=\"_blank\">Weak guidance sends Dave &amp; Buster's reeling</a> (Jan. 8)</li>     <li><a href=\"https://seekingalpha.com/news/search?query=%23ICR18\" target=\"_blank\">#ICR18</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3321713\" data-linked=\"Restaurant sector jittery as ICR updates roll in\" data-tweet=\"$PLAY $PLAY $BJRI - Restaurant sector jittery as ICR updates roll in https://seekingalpha.com/news/3321713-restaurant-sector-jittery-icr-updates-roll-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3321713-restaurant-sector-jittery-icr-updates-roll-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321709\" data-ts=\"1515441311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321709-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+72%</font>. <a href='https://seekingalpha.com/symbol/ATNI' title='ATN International, Inc.'>ATNI</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MFGP' title='Micro Focus International plc ADR'>MFGP</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/DQ' title='DAQO New Energy Corp.'>DQ</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321709\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$MYSZ $ATNI $MARK - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3321709-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3321709-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321704\" data-ts=\"1515438509\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIBB\" target=\"_blank\">HIBB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321704-hibbett-sports-rallies-on-ncaa-football-tax-factors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hibbett Sports rallies on NCAA football, tax factors</a></h4><ul>     <li>Canaccord Genuity upgrades Hibbett Spports (<a href='https://seekingalpha.com/symbol/HIBB' title='Hibbett Sports, Inc.'>HIBB</a> <font color='green'>+4.8%</font>) to Buy from Hold.</li>     <li>Analyst Camilo Lyon sees a benefit for the retailer from tonight's University of Alabama vs. University of Georgia NCAA football championship game due to 18% of the Hibbett store chain being located in the states of Alabama and Georgia and the title game being played in Atlanta.</li>     <li>Lyon also estimates that Hibbett will pay a tax rate of 21.6% in 2019, compared to 37% in 2016.</li>     <li>Finally, there's seen some inventory management approved at Hibbett underway. \"HIBB has made significant progress in working down slow turning footwear platforms, and we believe the company will be in a much cleaner inventory position as it enters fiscal 2019,\" writes Lyon.</li><li>Source: Bloomberg, Benzinga</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321704\" data-linked=\"Hibbett Sports rallies on NCAA football, tax factors\" data-tweet=\"$HIBB - Hibbett Sports rallies on NCAA football, tax factors https://seekingalpha.com/news/3321704-hibbett-sports-rallies-on-ncaa-football-tax-factors?source=tweet\" data-url=\"https://seekingalpha.com/news/3321704-hibbett-sports-rallies-on-ncaa-football-tax-factors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321703\" data-ts=\"1515438224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321703-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ROYT' title='Pacific Coast Oil Trust'>ROYT</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/TMQ' title='Trilogy Metals Inc.'>TMQ</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/USAU' title='U.S. Gold Corp.'>USAU</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/EPE' title='EP Energy Corporation'>EPE</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BXE' title='Bellatrix Exploration Ltd'>BXE</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/WG' title='Willbros Group, Inc.'>WG</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321703\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$DELT-OLD $EMES $NOG - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3321703-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3321703-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321700\" data-ts=\"1515437768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321700-sarepta-sees-much-305m-in-exondys-51-sales-this-year-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta sees as much as $305M in Exondys 51 sales this year; shares up 1%</a></h4><ul><li>Sarepta Therapeutics (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+0.9%</font>) <a href=\"https://seekingalpha.com/pr/17040868-sarepta-therapeutics-pre-announces-fourth-quarter-2017-revenue-provides-full-year-2018\" target=\"_blank\">updates</a> investors at JPM18 on sales of DMD med EXONDYS 51 (eteplirsen).</li><li>Revenue for Q4 2017 and full year should be $57.3M and $154.6M, respectively. Consensus views are $55.8M and $153.9M, respectively.</li><li>For 2018, EXONDYS 51 should generate $295M - 305M (consensus: $301.4M).</li><li>#JPM18</li></ul><div class=\"tiny-share-widget\" data-id=\"3321700\" data-linked=\"Sarepta sees as much as $305M in Exondys 51 sales this year; shares up 1%\" data-tweet=\"$SRPT - Sarepta sees as much as $305M in Exondys 51 sales this year; shares up 1% https://seekingalpha.com/news/3321700-sarepta-sees-much-305m-in-exondys-51-sales-this-year-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3321700-sarepta-sees-much-305m-in-exondys-51-sales-this-year-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321698\" data-ts=\"1515437294\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPS\" target=\"_blank\">UPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321698-deutsche-bank-resets-expectations-on-ups-after-tax-reform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank resets expectations on UPS after tax reform</a></h4><ul> <li>Deutsche Bank analyst Amit Mehrota <a href=\"https://www.barrons.com/articles/underappreciated-ups-can-still-pack-a-punch-1515429973\" target=\"_blank\">adds</a> UPS (<a href='https://seekingalpha.com/symbol/UPS' title='United Parcel Service, Inc.'>UPS</a> <font color='green'>+0.8%</font>) to the list of companies that will see a share price boost due to the new tax legislation.</li> <li>\"We also estimate that tax reform equates to about $1B of incremental free cash flow per annum, reflecting higher net earnings (even after assuming 50% gets competed away) and lower cash taxes from 100% accelerated depreciation (equating to ~15% cash tax rate). Against this backdrop we view UPS shares as underappreciated and overly discounting a heightened investment cycle, with opportunity for sentiment to evolve this year from 'increasing capex' to 'peak capex', which should allow for multiple expansion,\" reasons Mehrota.</li> <li>\"This, together with &gt;2.5% dividend yield and higher earnings/free cash from corporate tax reform implies double-digit return potential,\" he adds.</li><li>The new DB price target on UPS is $145.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321698\" data-linked=\"Deutsche Bank resets expectations on UPS after tax reform\" data-tweet=\"$UPS - Deutsche Bank resets expectations on UPS after tax reform https://seekingalpha.com/news/3321698-deutsche-bank-resets-expectations-on-ups-after-tax-reform?source=tweet\" data-url=\"https://seekingalpha.com/news/3321698-deutsche-bank-resets-expectations-on-ups-after-tax-reform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321696\" data-ts=\"1515436815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CANF\" target=\"_blank\">CANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321696-can-fite-up-15-on-piclidenoson-distribution-deal-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Can-Fite up 15% on piclidenoson distribution deal in Europe</a></h4><ul><li>Thinly traded nano cap Can-Fite BioPharma (<a href='https://seekingalpha.com/symbol/CANF' title='Can-Fite BioPharma Ltd.'>CANF</a> <font color='green'>+15.4%</font>) is up more than a 7x surge in volume, albeit on turnover of only 290K shares, in response to its <a href=\"https://seekingalpha.com/pr/17039898-can-fite-signs-multi-million-dollar-distribution-agreement-piclidenoson-3-european-countries\" target=\"_blank\">distribution agreement</a> with Gebro Holding GmBH to distribute Can-Fite's piclidenoson (CF101) in Spain, Switzerland and Austria for the treatment of rheumatoid arthritis and psoriasis (after regulatory approvals).</li><li>Under the terms of the deal, Can-Fite will receive $2M in an upfront and milestone payment, up to $7M in additional payments and double-digit royalties on net sales.</li><li><strong>Update</strong>: On January 25, Can-Fite <a href=\"https://seekingalpha.com/pr/17055972-can-fite-receives-gebro-holdings-2200-000-payment-part-distribution-agreement-piclidenoson-3\" target=\"_blank\">announced </a>that it had received $2.2M from Gebro.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321696\" data-linked=\"Can-Fite up 15% on piclidenoson distribution deal in Europe\" data-tweet=\"$CANF - Can-Fite up 15% on piclidenoson distribution deal in Europe https://seekingalpha.com/news/3321696-can-fite-up-15-on-piclidenoson-distribution-deal-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3321696-can-fite-up-15-on-piclidenoson-distribution-deal-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321694\" data-ts=\"1515436191\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMU\" target=\"_blank\">IMMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321694-immunomedics-monetizes-royalties-from-cancer-candidate-immuminus-132-for-250m-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immunomedics monetizes royalties from cancer candidate IMMU-132 for $250M; shares up 1%</a></h4><ul><li>Immunomedics (<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='green'>+0.8%</font>) inks an <a href=\"https://seekingalpha.com/pr/17040207-immunomedics-royalty-pharma-announce-royalty-funding-stock-purchase-agreements-totalling-250\" target=\"_blank\">agreement </a>with Royalty Pharma to sell tiered royalties on net sales of cancer med sacituzumab govitecan (IMMU-132) for $175M in cash. Royalty has also purchased ~4.37M shares of Immunomedics common stock at $17.15 per share totaling $75M.</li><li>The royalty rate starts at 4.15% on net sales up to $2B, then declines step-wise to 1.75% on global net sales greater than $6B.</li><li>The company says the funding will support the continued development of sacituzumab govitecan.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321694\" data-linked=\"Immunomedics monetizes royalties from cancer candidate IMMU-132 for $250M; shares up 1%\" data-tweet=\"$IMMU - Immunomedics monetizes royalties from cancer candidate IMMU-132 for $250M; shares up 1% https://seekingalpha.com/news/3321694-immunomedics-monetizes-royalties-from-cancer-candidate-immuminus-132-for-250m-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3321694-immunomedics-monetizes-royalties-from-cancer-candidate-immuminus-132-for-250m-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321693\" data-ts=\"1515436025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321693-cnbc-gopro-hires-jpmorgan-to-evaluate-sale-of-company-shares-trim-losses-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNBC: GoPro hires JPMorgan to evaluate sale of company; shares trim losses (updated)</a></h4><ul>     <li>GoPro (<a href=\"http://seekingalpha.com/symbol/GPRO\" target=\"_blank\">GPRO</a> <font color='red'>-10.9%</font>), one of today's top losers after <a href=\"https://seekingalpha.com/news/3321651-gopro-minus-22-percent-q4-forecast-cut-product-discount\" target=\"_blank\">slashing its Q4 revenue forcast</a>, heavily discounting its Hero6 cameras and planning layoffs, is trimming losses after CNBC reports the company has <a href=\"https://www.cnbc.com/2018/01/08/gopro-has-hired-jp-morgan-to-put-itself-up-for-sale.html\" target=\"_blank\">hired JPMorgan to put itself up for sale</a>.</li>     <li>CEO Nick Woodman said the plan is to remain independent, but \"If there are opportunities for us to unite with a bigger parent company to scale GoPro even bigger, that is something that we would look at.\"</li>     <li>JPMorgan had helped underwrite the company's 2014 IPO; it's not clear whether there's an interested buyer as of yet.</li>   <li>Shares are paring a <font color='red'>decline that reached 33%</font> at the bottom today.</li><li><strong>Updated 2:39 p.m.:</strong> Woodman says the company has not engaged with JPMorgan on a sale.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3321693\" data-linked=\"CNBC: GoPro hires JPMorgan to evaluate sale of company; shares trim losses (updated)\" data-tweet=\"$GPRO - CNBC: GoPro hires JPMorgan to evaluate sale of company; shares trim losses (updated) https://seekingalpha.com/news/3321693-cnbc-gopro-hires-jpmorgan-to-evaluate-sale-of-company-shares-trim-losses-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3321693-cnbc-gopro-hires-jpmorgan-to-evaluate-sale-of-company-shares-trim-losses-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321692\" data-ts=\"1515435251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321692-apple-watch-control-coming-to-whirlpool-appliances-keybanc-sees-poor-iphone-x-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple Watch control coming to Whirlpool appliances; KeyBanc sees poor iPhone X sales</a></h4><ul><li>        Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) Watch users will soon have the ability to control Whirlpool (NYSE:<a href='https://seekingalpha.com/symbol/WHR' title='Whirlpool Corporation'>WHR</a>) appliances through the wearable.</li><li>               Whirlpool <a href=\"https://www.cnbc.com/2018/01/08/apple-watch-to-be-able-to-control-whirlpool-appliances-this-year.html\" target=\"_blank\">announced</a> the development at CES and said the compatibility would come later this year to 20 connected appliances.&nbsp;</li><li>               Whirlpool says Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) Alexa and Google (NASDAQ:<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>) Assistant voice controls will also arrive in 2018.&nbsp;</li><li>                  In other Apple news, KeyBanc analyst John Vinh <a href=\"https://www.cnbc.com/2018/01/08/keybanc-capital-markets-says-iphone-x-sales-are-worse-than-expected.html\" target=\"_blank\">suggests</a> that recent Taiwanese media allegations of low iPhone X orders could prove true.    </li><li>               Vinh writes that iPhone X &ldquo;feedback indicates sell-through has been somewhat disappointing&rdquo; and that the premium model fell short of the 8/8 Plus &ldquo;due to the price tag and limited promotion.&rdquo;</li><li>               Vinh says conversations with carriers revealed &ldquo;worse-than-expected iPhone X demand.&rdquo;&nbsp;</li><li>               The analyst also lowered his rating for Cirrus Logic (NASDAQ:<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a>), which gets 79% of its revenue from Apple. &nbsp;&nbsp;</li><li>                  Apple shares are&nbsp;<font color='red'>down 0.2%</font>.    </li><li>                  Cirrus Logic shares are&nbsp;<font color='red'>down 0.95%</font>.&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3320010-apple-suppliers-drop-iphone-x-sales-report\" target=\"_blank\">Apple, suppliers drop on iPhone X sales report</a> (Dec. 26, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320049-rosenblatt-defends-apple-iphone-x-sale-cut\" target=\"_blank\">Rosenblatt defends Apple on iPhone X sale cut</a> (Dec. 26, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320693-apple-analyst-says-low-iphone-x-estimates-still-high\" target=\"_blank\">Apple analyst says low iPhone X estimates still \"too high\"</a> (Jan. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321692\" data-linked=\"Apple Watch control coming to Whirlpool appliances; KeyBanc sees poor iPhone X sales\" data-tweet=\"$AAPL $AAPL $WHR - Apple Watch control coming to Whirlpool appliances; KeyBanc sees poor iPhone X sales https://seekingalpha.com/news/3321692-apple-watch-control-coming-to-whirlpool-appliances-keybanc-sees-poor-iphone-x-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3321692-apple-watch-control-coming-to-whirlpool-appliances-keybanc-sees-poor-iphone-x-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321689\" data-ts=\"1515434980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321689-gm-aims-for-new-segment-cadillac-xt4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GM aims for new segment with Cadillac XT4</a></h4><ul> <li>General Motors (<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a> <font color='green'>+1%</font>) is <a href=\"https://www.bloomberg.com/news/articles/2018-01-08/cadillac-is-said-to-ready-small-suv-to-jumpstart-weak-u-s-sales\" target=\"_blank\">prepping</a> a plant in Kansas City to build a new Cadillac crossover, sources tell Bloomberg.</li> <li>The Cadillac XT4, positioned beneath the larger XT5, is expected to be built using some underpinning from the KC-produced Chevrolet Malibu in a cost-savings move.</li> <li>The XT4 will compete against the BMW X3 and Audi Q3.</li> <li>Sneak peek: Kelley Blue Book posted some <a href=\"https://www.kbb.com/car-news/all-the-latest/2019-cadillac-xt4-spied/2100005010/\" target=\"_blank\">spy shots</a> of the XT4.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321689\" data-linked=\"GM aims for new segment with Cadillac XT4\" data-tweet=\"$GM - GM aims for new segment with Cadillac XT4 https://seekingalpha.com/news/3321689-gm-aims-for-new-segment-cadillac-xt4?source=tweet\" data-url=\"https://seekingalpha.com/news/3321689-gm-aims-for-new-segment-cadillac-xt4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321688\" data-ts=\"1515434481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPCN\" target=\"_blank\">LPCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321688-ad-comm-review-approaches-for-lipocines-oral-testosterone-replacement-med-tlando-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad Comm review approaches for Lipocine&#39;s oral testosterone replacement med Tlando; shares ahead 17%</a></h4><ul><li>The FDA's Bone, Reproductive and Urologic Drugs Advisory Committee will <a href=\"https://www.fda.gov/AdvisoryCommittees/Calendar/ucm585818.htm\" target=\"_blank\">meet </a>on Wednesday, January 10 to discuss Lipocine's (<a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a> <font color='green'>+16.5%</font>) marketing application seeking approval for TLANDO (testosterone undecanoate) for the treatment of low testosterone in hypogonadal males.</li><li>The advisory committee will meet tomorrow to discuss the marketing application from competitor Clarus Therapeutics for JATENZO (testosterone undecanoate) for the same indication.</li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM591569.pdf\" target=\"_blank\">FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM591570.pdf\" target=\"_blank\">Errata to FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM591571.pdf\" target=\"_blank\">Lipocine briefing doc&nbsp;</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3321471-ad-com-next-week-clarus-therapeutics-oral-testosterone\" target=\"_blank\">Ad Com next week for Clarus Therapeutics' oral testosterone</a> (Jan. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321688\" data-linked=\"Ad Comm review approaches for Lipocine&#39;s oral testosterone replacement med Tlando; shares ahead 17%\" data-tweet=\"$LPCN - Ad Comm review approaches for Lipocine&#39;s oral testosterone replacement med Tlando; shares ahead 17% https://seekingalpha.com/news/3321688-ad-comm-review-approaches-for-lipocines-oral-testosterone-replacement-med-tlando-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3321688-ad-comm-review-approaches-for-lipocines-oral-testosterone-replacement-med-tlando-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321686\" data-ts=\"1515434395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321686-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+70%</font>. <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/APHB' title='AmpliPhi Biosciences Corp.'>APHB</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/SIFY' title='Sify Technologies Limited'>SIFY</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/AMSC' title='American Superconductor Corporation'>AMSC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/NVRO' title='Nevro'>NVRO</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CBMG' title='Cellular Biomedicine Group, Inc.'>CBMG</a> <font color='green'>+16%</font>.</li>     <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='red'>-51%</font>. <a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/MFGP' title='Micro Focus International plc ADR'>MFGP</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/BABY' title='Natus Medical Incorporated'>BABY</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/OXFD' title='Oxford Immunotec Global PLC'>OXFD</a> <font color='red'>-15%</font>.</li> &nbsp;     &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3321686\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MYSZ $DELT-OLD $ARMP - Midday Gainers / Losers https://seekingalpha.com/news/3321686-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3321686-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321683\" data-ts=\"1515433413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVXS\" target=\"_blank\">AVXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321683-avexis-expands-partnership-regenxbio-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AveXis expands partnership with REGENXBIO; shares up 4%</a></h4><ul><li>AveXis (<a href='https://seekingalpha.com/symbol/AVXS' title='AveXis'>AVXS</a> <font color='green'>+3.5%</font>) <a href=\"https://seekingalpha.com/pr/17039982-regenxbio-avexis-announce-expansion-relationship-amended-license-agreement-development\" target=\"_blank\">goes all in</a> with REGENXBIO (<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a> <font color='red'>-5.2%</font>) by expanding its 2014 global license agreement focused on spinal muscular atrophy &#40;SMA&#41;. Its lead candidate, AVXS-101, used REGENXBIO's NAV AAV9 vector.</li><li>Under the terms of the updated agreement, REGENXBIO grants AveXis exclusive global rights to all vectors in its NAV Technology Platform for the treatment of SMA in addition to amending certain terms. AveXis will pay $80M upfront, another $30M in a year, another $30M in two years, up to $120M in milestones and low double-digit royalties on net sales of all commercial SMA products using an NAV vector other than NAV AAV9.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321460-avexis-volatile-update-lead-candidate-avxsminus-101\" target=\"_blank\">AveXis volatile after update on lead candidate AVXS-101</a> (Jan. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321683\" data-linked=\"AveXis expands partnership with REGENXBIO; shares up 4%\" data-tweet=\"$AVXS $AVXS $RGNX - AveXis expands partnership with REGENXBIO; shares up 4% https://seekingalpha.com/news/3321683-avexis-expands-partnership-regenxbio-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3321683-avexis-expands-partnership-regenxbio-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321682\" data-ts=\"1515433091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HDP\" target=\"_blank\">HDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321682-hortonworksminus-4-on-analyst-downgrade-end-of-bull-thesis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hortonworks -4% on analyst downgrade, end of bull thesis</a></h4><ul><li>        Barclays <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=2&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwio85-S88jYAhVF3FMKHY-mAe0QFggtMAE&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BComments%2FBarclays%2BDowngrades%2BHortonworks%2B%28HDP%29%2Bto%2BEqualweight%2F13662302.html&amp;usg=AOvVaw1mUyMvA9kp8FBJ4rAtnwoV\" target=\"_blank\">downgrades</a> Hortonworks (NASDAQ:<a href='https://seekingalpha.com/symbol/HDP' title='Hortonworks'>HDP</a>) from Overweight to Equal Weight with a $22 price target.</li><li>               Analyst Raimo Lenschow steps to the side as the bull thesis for Hortonworks&rsquo; valuation closing the valuation gap with Cloudera has played out.&nbsp;</li><li>               Hortonworks shares are&nbsp;<font color='green'>down 4%</font>&nbsp;to $19.92.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319911-top-winners-tech-2017\" target=\"_blank\">Top winners in tech for 2017</a> (Dec. 22, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321682\" data-linked=\"Hortonworks -4% on analyst downgrade, end of bull thesis\" data-tweet=\"$HDP - Hortonworks -4% on analyst downgrade, end of bull thesis https://seekingalpha.com/news/3321682-hortonworksminus-4-on-analyst-downgrade-end-of-bull-thesis?source=tweet\" data-url=\"https://seekingalpha.com/news/3321682-hortonworksminus-4-on-analyst-downgrade-end-of-bull-thesis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321679\" data-ts=\"1515432725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APPN\" target=\"_blank\">APPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321679-appianminus-6_8-on-analyst-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Appian -6.8% on analyst downgrade</a></h4><ul><li>        Barclays <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20180108110611SUMRX\" target=\"_blank\">downgrades</a> Appian (NASDAQ:<a href='https://seekingalpha.com/symbol/APPN' title='Appian Corp.'>APPN</a>) from Equal Weight to Underweight.</li><li>               Latest analyst <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=APPN:NMQ\" target=\"_blank\">recommendations</a>: 1 Buy, 1 Outperform, and 6 Hold.&nbsp;</li><li>               Median price target: $22.50.&nbsp;&nbsp;</li><li>               Appian shares are&nbsp;<font color='red'>down 6.8%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3321679\" data-linked=\"Appian -6.8% on analyst downgrade\" data-tweet=\"$APPN - Appian -6.8% on analyst downgrade https://seekingalpha.com/news/3321679-appianminus-6_8-on-analyst-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3321679-appianminus-6_8-on-analyst-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321677\" data-ts=\"1515432168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MB\" target=\"_blank\">MB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321677-mindbodyplus-5_7-on-analyst-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mindbody +5.7% on analyst upgrade</a></h4><ul><li>        Jefferies <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20180108110611SUMRX\" target=\"_blank\">upgrades</a> Mindbody (NASDAQ:<a href='https://seekingalpha.com/symbol/MB' title='Mindbody'>MB</a>) from Hold to Buy and raises its price target by $9 to $40.</li><li>               Latest analyst <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=MB:NMQ\" target=\"_blank\">recommendations</a>: 3 Buy, 7 Outperform, and 2 Hold.&nbsp;</li><li>               Median price target: $34.&nbsp;</li><li>               Mindbody shares are&nbsp;<font color='green'>up 5.7%</font>.&nbsp; &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3321677\" data-linked=\"Mindbody +5.7% on analyst upgrade\" data-tweet=\"$MB - Mindbody +5.7% on analyst upgrade https://seekingalpha.com/news/3321677-mindbodyplus-5_7-on-analyst-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3321677-mindbodyplus-5_7-on-analyst-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321676\" data-ts=\"1515432012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OXFD\" target=\"_blank\">OXFD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321676-oxford-immunotec-sees-q4-top-line-of-25m-shy-of-consensus-shares-down-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oxford Immunotec sees Q4 top line of ~$25M, shy of consensus; shares down 15%</a></h4><ul><li>Thinly traded micro cap Oxford Immunotec (<a href='https://seekingalpha.com/symbol/OXFD' title='Oxford Immunotec Global PLC'>OXFD</a> <font color='red'>-14.7%</font>) slumps on a 4x surge in volume on the heels of its <a href=\"https://seekingalpha.com/pr/17040227-oxford-immunotec-announces-preliminary-revenue-fourth-quarter-full-year-2017\" target=\"_blank\">announcement </a>of preliminary results for Q4 2017 and full-year.</li><li>Management expects revenue in the final quarter and full-year 2017 to be $24.9M - 25.4M and $103.0M - 104.5M, respectively. Consensus views for the quarter and year are $26.1M and $104.1M, respectively.</li><li>Final results will be released on Tuesday, February 27 before the open. The company will provide its 2018 outlook at that time.</li><li>$JPM18</li></ul><div class=\"tiny-share-widget\" data-id=\"3321676\" data-linked=\"Oxford Immunotec sees Q4 top line of ~$25M, shy of consensus; shares down 15%\" data-tweet=\"$OXFD - Oxford Immunotec sees Q4 top line of ~$25M, shy of consensus; shares down 15% https://seekingalpha.com/news/3321676-oxford-immunotec-sees-q4-top-line-of-25m-shy-of-consensus-shares-down-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3321676-oxford-immunotec-sees-q4-top-line-of-25m-shy-of-consensus-shares-down-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321674\" data-ts=\"1515431319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVRO\" target=\"_blank\">NVRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321674-fda-oks-nevros-senza-ii-scs-shares-ahead-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Nevro&#39;s Senza II SCS; shares ahead 16%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17040049-nevro-receives-fda-approval-senza-ii-spinal-cord-stimulation-system-delivering-hf10-therapy\" target=\"_blank\">approves </a>Nevro's (<a href='https://seekingalpha.com/symbol/NVRO' title='Nevro'>NVRO</a> <font color='green'>+16.1%</font>) next-generation Senza II Spinal Cord Stimulation &#40;SCS&#41; System delivering HF10 therapy for pain relief. The device has a smaller, more refined footprint than the current Implantable Pulse Generator.</li><li>The company says <a href=\"http://www.nevro.com/English/Physicians/HF10-Therapy-Superiority/default.aspx\" target=\"_blank\">HF10 therapy</a> is the only SCS approach that relieves pain without the <a href=\"https://en.wikipedia.org/wiki/Paresthesia\" target=\"_blank\">paresthesia </a>(tingling or buzzing sensation).</li></ul><div class=\"tiny-share-widget\" data-id=\"3321674\" data-linked=\"FDA OKs Nevro&#39;s Senza II SCS; shares ahead 16%\" data-tweet=\"$NVRO - FDA OKs Nevro&#39;s Senza II SCS; shares ahead 16% https://seekingalpha.com/news/3321674-fda-oks-nevros-senza-ii-scs-shares-ahead-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3321674-fda-oks-nevros-senza-ii-scs-shares-ahead-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321673\" data-ts=\"1515431208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPCB\" target=\"_blank\">SPCB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321673-supercomplus-2_3-on-cryptocurrency-plans\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SuperCom +2.3% on cryptocurrency plans</a></h4><ul><li>        SuperCom (NASDAQ:<a href='https://seekingalpha.com/symbol/SPCB' title='SuperCom, Ltd.'>SPCB</a>) <a href=\"https://seekingalpha.com/pr/17040363-supercom-develop-bitcoin-cryptocurrency-capabilities-mobile-money-suite-superpay\" target=\"_blank\">announces</a> that its in the process of &ldquo;developing various cryptocurrency capabilities&rdquo; for its mobile money suite SuperPay.</li><li>               SuperCom shares are&nbsp;<font color='green'>up 2.3%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3321673\" data-linked=\"SuperCom +2.3% on cryptocurrency plans\" data-tweet=\"$SPCB - SuperCom +2.3% on cryptocurrency plans https://seekingalpha.com/news/3321673-supercomplus-2_3-on-cryptocurrency-plans?source=tweet\" data-url=\"https://seekingalpha.com/news/3321673-supercomplus-2_3-on-cryptocurrency-plans\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321672\" data-ts=\"1515431193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROW\" target=\"_blank\">TROW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321672-t-rowe-price-upgraded-invesco-cut-baml\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T. Rowe Price upgraded, Invesco cut at BAML</a></h4><ul><li>Analyst Michael Carrier decides to go with the hotter hand, upgrading T. Rowe Price (<a href='https://seekingalpha.com/symbol/TROW' title='T. Rowe Price Group, Inc.'>TROW</a> <font color='green'>+2.1%</font>) to Buy and downgrading Invesco (<a href='https://seekingalpha.com/symbol/IVZ' title='Invesco Ltd.'>IVZ</a> <font color='red'>-1.2%</font>) to Neutral.</li><li>TROW is&nbsp;<font color='green'>up 45%</font>&nbsp;Y/Y, while Invesco has&nbsp;<font color='green'>gained 17%</font>.</li><li>Looking at relative growth prospects, financial strength, valuation, and regulatory issues, T. Rowe has the advantage, says Carrier.</li><li>Ahead of Q4 results, Carrier is a fan of Franklin Templeton (<a href='https://seekingalpha.com/symbol/BEN' title='Franklin Resources Inc.'>BEN</a> <font color='green'>+0.6%</font>) thanks to recent underperformance and $6B of cash it can now repatriate at a more favorable tax rate. Also favored is Carlyle Group (<a href='https://seekingalpha.com/symbol/CG' title='The Carlyle Group'>CG</a> <font color='red'>-0.6%</font>), Blackstone (<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a> <font color='green'>+0.5%</font>), Ameritrade (<a href='https://seekingalpha.com/symbol/AMTD' title='TD Ameritrade Holding Corporation'>AMTD</a> <font color='green'>+1%</font>), and Northern&nbsp; Trust (<a href='https://seekingalpha.com/symbol/NTRS' title='Northern Trust Corporation'>NTRS</a>).</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3321672\" data-linked=\"T. Rowe Price upgraded, Invesco cut at BAML\" data-tweet=\"$TROW $TROW $IVZ - T. Rowe Price upgraded, Invesco cut at BAML https://seekingalpha.com/news/3321672-t-rowe-price-upgraded-invesco-cut-baml?source=tweet\" data-url=\"https://seekingalpha.com/news/3321672-t-rowe-price-upgraded-invesco-cut-baml\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321671\" data-ts=\"1515431130\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCX\" target=\"_blank\">TCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321671-tucowsminus-4_5-copperfield-sees-70-downside-in-broken-firm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tucows -4.5% as Copperfield sees 70% downside in &#39;broken&#39; firm</a></h4><ul>   <li>Tucows (NYSEMKT:<a href='https://seekingalpha.com/symbol/TCX' title='Tucows Inc'>TCX</a>) has <font color='red'>slipped 4.5%</font> amid a <a href=\"https://www.scribd.com/document/368674865/Tucows-Inc-TCX-Cashing-in-on-Neo-Nazis-Child-Porn-A-Hidden-Lawsuit-as-Insiders-Dump\" target=\"_blank\">report from Copperfield</a> pointing to \"three structurally broken business segments\" and a \"laundry list of accounting shenanigans and financial irregularities.\"</li>    <li>In a harsh report titled \"Cashing in on Neo-Nazis, Child Porn, &amp; a Hidden Lawsuit as Insiders Dump,\" Copperfield sets the Internet service provider's fair value at $20, a fraction of current price of $58.85. (h/t <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable Calls</a>)</li>       <li>That target \"generously ignores\" risks from undisclosed litigation with the company's biggest domain reseller, Copperfield notes. Tucows stands to lose about 11% of its registered domains in that lawsuit.</li>    <li>The company's also been reporting revenue and EBITDA from domains that should have already been transferred, the report says.</li>    <li>Meanwhile, the domains business \"openly enables and supports neo-Nazism, pedophilia and bigotry,\" Copperfield charges.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321671\" data-linked=\"Tucows -4.5% as Copperfield sees 70% downside in &#39;broken&#39; firm\" data-tweet=\"$TCX - Tucows -4.5% as Copperfield sees 70% downside in &#39;broken&#39; firm https://seekingalpha.com/news/3321671-tucowsminus-4_5-copperfield-sees-70-downside-in-broken-firm?source=tweet\" data-url=\"https://seekingalpha.com/news/3321671-tucowsminus-4_5-copperfield-sees-70-downside-in-broken-firm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321669\" data-ts=\"1515430988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321669-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/DLA' title='Delta Apparel, Inc'>DLA</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321669\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$VUZI $WATT $CROX - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3321669-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3321669-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321665\" data-ts=\"1515430657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WATT\" target=\"_blank\">WATT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321665-energous-opens-preorders-for-first-wattup-enabled-products-sharesplus-13_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energous opens preorders for first WattUp-enabled products; shares +13.5%</a></h4><ul><li>        Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a>) <a href=\"https://seekingalpha.com/pr/17039903-energous-announces-first-wattup-enabled-consumer-products-available-via-pre-sale-ces-2018\" target=\"_blank\">opens preorders</a> for its first WattUp-enabled consumer product.</li><li>               The product is smart apparel from Myant SKIIN that allows users to track and measure health vitals. The apparel has the WattUp receiver embedded into the smart sensor and a WattUp Near Field transmitter in-box, which makes for easier sensor removal and charging.&nbsp;</li><li>               Energous plans to demonstrate WattUp-enabled hearing aids from Delight and SK Telesys and WattUp chipsets with Dialog Semiconductor during CES. The Delight hearing aids are expected to launch this year.&nbsp;</li><li>               Energous shares are&nbsp;<font color='green'>up 13.5%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320092-energous-plus-63-percent-fcc-certification\" target=\"_blank\">Energous +63% on FCC certification</a> (Dec. 26, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320307-roth-capital-raises-energous-price-target-fcc-chair-tweets-confirmation\" target=\"_blank\">Roth Capital raises its Energous price target; FCC chair tweets confirmation</a> (Dec. 28, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320325-energous-competitor-receives-fcc-approval\" target=\"_blank\">Energous competitor receives FCC approval</a> (Dec. 28, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320434-citron-research-tweets-energous-history-deception-shares-drop-6_4-percent\" target=\"_blank\">Citron Research tweets Energous' \"history of deception\"; shares drop 6.4%</a> (Dec. 29, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320635-energous-ceo-discloses-share-sale\" target=\"_blank\">Energous CEO discloses share sale</a> (Jan. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321665\" data-linked=\"Energous opens preorders for first WattUp-enabled products; shares +13.5%\" data-tweet=\"$WATT - Energous opens preorders for first WattUp-enabled products; shares +13.5% https://seekingalpha.com/news/3321665-energous-opens-preorders-for-first-wattup-enabled-products-sharesplus-13_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3321665-energous-opens-preorders-for-first-wattup-enabled-products-sharesplus-13_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321664\" data-ts=\"1515430591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321664-start-of-jpm18-fails-to-buoy-healthcare-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Start of JPM18 fails to buoy healthcare stocks</a></h4><ul><li>The start of JPMorgan's healthcare conference has started with a whimper with no significant news to boost biopharma or biotech stocks. Most issues are under pressure in early trading.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='red'>-0.5%</font>)(<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='red'>-2.3%</font>)(<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+0.2%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='red'>-0.7%</font>)(<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='red'>-3.9%</font>)(<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color='red'>-0.3%</font>)(<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='red'>-1.8%</font>)(<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='red'>-1.9%</font>)(<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='red'>-1.1%</font>)(<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-0.2%</font>)(<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='red'>-1%</font>)(<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color='red'>-0.9%</font>)(<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='red'>-0.7%</font>)(<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='red'>-1.3%</font>)(<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='red'>-0.4%</font>)(<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color='red'>-0.4%</font>)(<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a> <font color='red'>-4.7%</font>)(VRX <font color='red'>-4.2%</font>)</li><li>ETFs: (<a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a> <font color='red'>-3.8%</font>)(<a href='https://seekingalpha.com/symbol/GRX' title='The Gabelli Healthcare & Wellness Rx Trust'>GRX</a> <font color='red'>-0.5%</font>)(<a href='https://seekingalpha.com/symbol/THW' title='Tekla World Healthcare Fund'>THW</a> <font color='red'>-0.1%</font>)(<a href='https://seekingalpha.com/symbol/BME' title='BlackRock Health Sciences Trust'>BME</a> <font color='red'>-0.2%</font>)(<a href='https://seekingalpha.com/symbol/CNCR' title='Loncar Cancer Immunotherapy ETF'>CNCR</a> <font color='red'>-2%</font>)(<a href='https://seekingalpha.com/symbol/IXJ' title='iShares Global Healthcare ETF'>IXJ</a> <font color='red'>-0.8%</font>)(<a href='https://seekingalpha.com/symbol/ARKG' title='ARK Genomic Revolution Multi-Sector ETF'>ARKG</a> <font color='red'>-3.3%</font>)(<a href='https://seekingalpha.com/symbol/GNRX' title='VanEck Vectors Generic Drugs ETF'>GNRX</a>)(<a href='https://seekingalpha.com/symbol/PJP' title='Invesco Dynamic Pharmaceuticals Portfolio ETF'>PJP</a> <font color='red'>-1.8%</font>)(<a href='https://seekingalpha.com/symbol/IHE' title='iShares U.S. Pharmaceuticals ETF'>IHE</a> <font color='red'>-1.4%</font>)(<a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a> <font color='red'>-1.5%</font>)(<a href='https://seekingalpha.com/symbol/PPH' title='VanEck Vectors Pharmaceutical ETF'>PPH</a> <font color='red'>-1.1%</font>)(<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='red'>-1.7%</font>)(<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color='red'>-2.1%</font>)</li><li>#JPM18</li></ul><div class=\"tiny-share-widget\" data-id=\"3321664\" data-linked=\"Start of JPM18 fails to buoy healthcare stocks\" data-tweet=\"$GILD $GILD $CELG - Start of JPM18 fails to buoy healthcare stocks https://seekingalpha.com/news/3321664-start-of-jpm18-fails-to-buoy-healthcare-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3321664-start-of-jpm18-fails-to-buoy-healthcare-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321667\" data-ts=\"1515430371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSPE\" target=\"_blank\">GSPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321667-gulfslope-energy-texas-south-energy-enter-strategic-partnership-delek-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GulfSlope Energy &amp; Texas South Energy enter into strategic partnership with Delek Group</a></h4><ul>     <li>GulfSlope Energy (<a href='https://seekingalpha.com/symbol/GSPE' title='Gulfslope Energy, Inc.'>OTCQB:GSPE</a>) &amp; Texas South Energy (<a href='https://seekingalpha.com/symbol/TXSO' title='Texas South Energy, Inc.'>OTCPK:TXSO</a>) jointly has entered into a strategic partnership with Delek Group.</li>     <li>The Companies and Delek have mutually agreed to pursue oil and natural gas opportunities in the Gulf of Mexico.</li>     <li>The initial transaction of this partnership is the execution of a participation agreement, whereby Delek GOM Investments LLC, a subsidiary of Delek, acquired rights to a 75% record title interest in 9 prospects (Photon, Quark, Pomeron, Tau, Tanker, Graviton, Tachyon, Selectron, and Canoe) in the shallow waters of the Gulf of Mexico.</li>     <li>GulfSlope will retain a 20% record title interest and Texas South will retain a 5% record title interest in each of these nine prospects.</li>     <li>Delek shall bear 90% of the gross cost and expense for each well until the test well reaches its objective depth. Thereafter, Delek will be responsible for 75% of the costs and expenses and GulfSlope and Texas South will be responsible for their pro-rata ownership interest of all such remaining costs and expenses while partially carried and thereafter.</li>     <li>In addition, Delek shall pay $1.5M to the Companies (73% to GulfSlope and 27% to Texas South) upon the filing of each well's exploration plan with the BOEM.</li>     <li>Delek shall have the right to acquire up to 20% of the issued and outstanding shares of common stock of each of GulfSlope and Texas South based on achieving certain milestones.</li><li><a href=\"https://seekingalpha.com/pr/17040294-gulfslope-energy-inc-texas-south-energy-inc-enter-strategic-partnership-delek-group-ltd\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3321667\" data-linked=\"GulfSlope Energy &amp; Texas South Energy enter into strategic partnership with Delek Group\" data-tweet=\"$GSPE $GSPE $TXSO - GulfSlope Energy &amp; Texas South Energy enter into strategic partnership with Delek Group https://seekingalpha.com/news/3321667-gulfslope-energy-texas-south-energy-enter-strategic-partnership-delek-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3321667-gulfslope-energy-texas-south-energy-enter-strategic-partnership-delek-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321663\" data-ts=\"1515429097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABBV\" target=\"_blank\">ABBV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321663-abbvies-upadacitinib-nabs-accelerated-review-status-in-u-s-for-atopic-dermatitis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AbbVie&#39;s upadacitinib nabs accelerated review status in U.S. for atopic dermatitis</a></h4><ul><li>The FDA designates AbbVie's (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='red'>-2.4%</font>) JAK1 inhibitor upadacitinib a Breakthrough Therapy for treatment of atopic dermatitis. A Phase 3 study should launch by Q2.</li><li>Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321181-fda-tags-novartis-shire-candidates-breakthrough-therapies\" target=\"_blank\">FDA tags Novartis and Shire candidates Breakthrough Therapies</a> (Jan. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321663\" data-linked=\"AbbVie&#39;s upadacitinib nabs accelerated review status in U.S. for atopic dermatitis\" data-tweet=\"$ABBV - AbbVie&#39;s upadacitinib nabs accelerated review status in U.S. for atopic dermatitis https://seekingalpha.com/news/3321663-abbvies-upadacitinib-nabs-accelerated-review-status-in-u-s-for-atopic-dermatitis?source=tweet\" data-url=\"https://seekingalpha.com/news/3321663-abbvies-upadacitinib-nabs-accelerated-review-status-in-u-s-for-atopic-dermatitis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321662\" data-ts=\"1515428943\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXLG\" target=\"_blank\">DXLG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321662-destination-xl-group-lower-after-soft-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Destination XL Group lower after soft guidance</a></h4><ul> <li>Destination XL Group (<a href='https://seekingalpha.com/symbol/DXLG' title='Destination XL Group, Inc.'>DXLG</a> <font color='red'>-8.7%</font>)&nbsp;<a href=\"https://seekingalpha.com/pr/17039828-destination-xl-group-inc-announces-holiday-sales-results\" target=\"_blank\">reports</a> comparable sales were up 3.0% during the two-month holiday period ending on December 30.</li> <li>Comparable sales were up 0.9% in November and 4.3% in December.</li> <li>Total sales increased 3.5% to $101.3M.</li> <li>Destination XL expects to achieve the low-end of the range of its previously announced guidance for FY17.</li><li>The guidance update was provided ahead of the company's ICR presentation.</li> <li><a href=\"https://seekingalpha.com/news/search?query=%23ICR18\" target=\"_blank\">#ICR18</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3321662\" data-linked=\"Destination XL Group lower after soft guidance\" data-tweet=\"$DXLG - Destination XL Group lower after soft guidance https://seekingalpha.com/news/3321662-destination-xl-group-lower-after-soft-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3321662-destination-xl-group-lower-after-soft-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321659\" data-ts=\"1515428385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CELG\" target=\"_blank\">CELG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321659-celgene-sees-17-increase-in-q4-2017-sales-full-year-earnings-up-25-lower-expected-growth-this\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celgene sees 17% increase in Q4 2017 sales, full-year earnings up 25%; lower expected growth this year pressures shares, down 4%</a></h4><ul><li>Celgene (<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='red'>-3.5%</font>) is under modest pressure after <a href=\"https://seekingalpha.com/pr/17040621-celgene-corporation-announces-preliminary-2017-unaudited-results-2018-financial-guidance\" target=\"_blank\">releasing </a>preliminary 2017 results and its outlook for this year.</li><li><strong>2017</strong>: Q4 revenue: $3.5B (+17%); EPS: ($0.09) - $0.46; non-GAAP EPS: ~$2.00. Full year: revenue: $13.0B (+16%); EPS: $3.64 - 4.19; non-GAAP EPS: ~$7.44.</li><li><strong>2018 guidance</strong>: revenue: $14.4B - 14.8B; EPS: $6.58 - 6.95; non-GAAP EPS: $8.70 - 8.90.</li><li>Key events this year: submit sNDA for Revlimid, in combination with bortezomib and dexamethasone, in newly diagnosed multiple myeloma. NDA filing for fedratinib in myelofibrosis.</li><li>Long-term targets: $19.0B - 20.0B in revenue and more than $12.50 in non-GAAP EPS in 2020.</li><li>$JPM18</li></ul><div class=\"tiny-share-widget\" data-id=\"3321659\" data-linked=\"Celgene sees 17% increase in Q4 2017 sales, full-year earnings up 25%; lower expected growth this year pressures shares, down 4%\" data-tweet=\"$CELG - Celgene sees 17% increase in Q4 2017 sales, full-year earnings up 25%; lower expected growth this year pressures shares, down 4% https://seekingalpha.com/news/3321659-celgene-sees-17-increase-in-q4-2017-sales-full-year-earnings-up-25-lower-expected-growth-this?source=tweet\" data-url=\"https://seekingalpha.com/news/3321659-celgene-sees-17-increase-in-q4-2017-sales-full-year-earnings-up-25-lower-expected-growth-this\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321658\" data-ts=\"1515427800\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321658-crypto-sector-lit-up-bright-red\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crypto sector lit up bright red</a></h4><ul><li>Bitcoin is<font color='red'> lower by 11%</font>&nbsp;and Litecoin<font color='red'> 9.5%</font>, to name a couple. The highflying Ripple is&nbsp;<font color='red'>down 15%</font>&nbsp;today, and&nbsp;<font color='red'>off 30%</font>&nbsp;from a peak hit last week.</li><li>Ether is lower today, but that's after surging over the weekend to a new record high of more than $1.2K.&nbsp;<font color='red'>Down 5%&nbsp;</font>on today's session, it's now at $1,074 vs. about $725 to start the year.</li><li><a href=\"https://www.reddit.com/r/CryptoCurrency/comments/7oxivj/cmc_just_tumbled_the_whole_market_with_one_move/\" target=\"_blank\">Making the rounds as traders look </a>for excuses: Popular valuation website <a href=\"https://coinmarketcap.com/\" target=\"_blank\">CoinMarketCap</a> today removed Korean exchanges from its price valuations. As valuations tend to be higher in Korea, price charts immediately took an ugly turn, prompting selling from the technicians who seem to make up the vast majority of crypto traders (sounds like forex).</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/BTLLF' title='Interbit Ltd.'>OTCPK:BTLLF</a> <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/UBIA' title='UBI BlockChain Internet Ltd.'>OTC:UBIA</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, PRELF, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a>, <a href='https://seekingalpha.com/symbol/CRCW' title='The Crypto Company'>OTC:CRCW</a>, <a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>, <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3321658\" data-linked=\"Crypto sector lit up bright red\" data-tweet=\"$GBTC $GBTC $COIN - Crypto sector lit up bright red https://seekingalpha.com/news/3321658-crypto-sector-lit-up-bright-red?source=tweet\" data-url=\"https://seekingalpha.com/news/3321658-crypto-sector-lit-up-bright-red\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>109&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321661\" data-ts=\"1515427756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSG\" target=\"_blank\">INSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321661-inseego-appoints-telematics-industry-veteran-mark-licht-to-board-of-directors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inseego Appoints Telematics Industry Veteran Mark Licht to its Board of Directors</a></h4><ul>     <li>Inseego Corp (NASDAQ:<a href='https://seekingalpha.com/symbol/INSG' title='Inseego Corp.'>INSG</a>) announced the appointment of Mark Licht to its Board of Directors, effective Jan. 5, 2018. Mark Licht has an extensive background in the telematics industry with over 25 years of experience in the formation, financing, and operation of wireless location services and technology companies.</li><li>Mr. Licht has founded several high-profile companies in the telematics and IoT markets, including Teletrac, Ituran, and Sigma One Communications. Currently, licht serves on the Boards or Advisory Boards of a number of fleet management, insurance telematics, data analytics, autonomous vehicle, predictive maintenance and OEM telematics companies in the US &amp; Latin America.</li>               <li>&ldquo;We&rsquo;re thrilled to have a high-profile industry expert such as Mark join our Board of Directors,&rdquo; said Dan Mondor, President and CEO of Inseego. &ldquo;Mark&rsquo;s extensive experience in both domestic and international telematics markets will be an extremely important asset to the Company as we look to strengthen the Ctrack brand and expand into exciting new verticals. Mark&rsquo;s entrepreneurial background and deep industry relationships bring fresh insights to Inseego which will help accelerate our transformation.&rdquo;</li><li>Shares&nbsp;<font color='green'>+6.25%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17040434-inseego-corp-appoints-telematics-industry-veteran-mark-licht-board-directors\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3321661\" data-linked=\"Inseego Appoints Telematics Industry Veteran Mark Licht to its Board of Directors\" data-tweet=\"$INSG - Inseego Appoints Telematics Industry Veteran Mark Licht to its Board of Directors https://seekingalpha.com/news/3321661-inseego-appoints-telematics-industry-veteran-mark-licht-to-board-of-directors?source=tweet\" data-url=\"https://seekingalpha.com/news/3321661-inseego-appoints-telematics-industry-veteran-mark-licht-to-board-of-directors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321650\" data-ts=\"1515427406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUVA\" target=\"_blank\">NUVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321650-nuvasive-sees-flat-q4-2017-sales-and-mid-single-digit-growth-this-year-shares-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NuVasive sees flat Q4 2017 sales and mid-single-digit growth this year; shares down 9%</a></h4><ul><li>On a <a href=\"https://seekingalpha.com/pr/17040187-nuvasive-announces-preliminary-unaudited-full-year-2017-revenue-results-preliminary-2018\" target=\"_blank\">preliminary basis</a>, NuVasive (<a href='https://seekingalpha.com/symbol/NUVA' title='NuVasive, Inc.'>NUVA</a> <font color='red'>-9.2%</font>) expects Q4 and 2017 revenues of $272M (flat) and $1.03B (+7%), respectively, in line with guidance provided on October 24, 2017.</li><li>Preliminary 2018 outlook: mid-single-digit revenue growth; at least a 1% increase in non-GAAP operating margin and non-GAAP EBITDA of $290M - 300M.</li><li>Final 2017 results and 2018 guidance, including the impact of the SafePassage transaction, will be announced in mid-February.</li><li>#JPM18</li></ul><div class=\"tiny-share-widget\" data-id=\"3321650\" data-linked=\"NuVasive sees flat Q4 2017 sales and mid-single-digit growth this year; shares down 9%\" data-tweet=\"$NUVA - NuVasive sees flat Q4 2017 sales and mid-single-digit growth this year; shares down 9% https://seekingalpha.com/news/3321650-nuvasive-sees-flat-q4-2017-sales-and-mid-single-digit-growth-this-year-shares-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3321650-nuvasive-sees-flat-q4-2017-sales-and-mid-single-digit-growth-this-year-shares-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321655\" data-ts=\"1515427380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHOO\" target=\"_blank\">SHOO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321655-steve-madden-updates-guidance-icr\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steve Madden updates guidance at ICR</a></h4><ul> <li>Steve Madden (<a href='https://seekingalpha.com/symbol/SHOO' title='Steven Madden, Ltd.'>SHOO</a> <font color='green'>+1.5%</font>) updates results ahead of its ICR presentation.</li><li>The retailer says Q4 sales rose 8.3% to $364.4M.&nbsp;Net sales for the wholesale division       increased 10.6% to $278.2M. Retail comparable store sales were down 5.1%.</li>          <li>The company expects FY17 EPS to be at the high end       of its prior guidance range.</li>     <li>\"Solid performance       in our wholesale business was offset by softness, as expected, in our       retail segment driven by weakness in the boot category. Overall, 2017       was a strong year for Steve Madden. We delivered robust sales and       earnings growth driven by the outstanding performance of our flagship       Steve Madden brand in the wholesale channel,\" says CEO Edward Rosenfeld.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17039756-steve-madden-announces-fourth-quarter-fiscal-year-2017-sales-results\" target=\"_blank\">Press Release</a></li><li><a href=\"https://seekingalpha.com/news/search?query=%23ICR18\" target=\"_blank\">#ICR18</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3321655\" data-linked=\"Steve Madden updates guidance at ICR\" data-tweet=\"$SHOO - Steve Madden updates guidance at ICR https://seekingalpha.com/news/3321655-steve-madden-updates-guidance-icr?source=tweet\" data-url=\"https://seekingalpha.com/news/3321655-steve-madden-updates-guidance-icr\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321628\" data-ts=\"1515427250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321628-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NVRO' title='Nevro'>NVRO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ALDR' title='Alder Biopharmaceuticals Inc.'>ALDR</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ABIO' title='ARCA biopharma, Inc.'>ABIO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='red'>-49%</font>. <a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='red'>-15%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321628\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$NVRO $ALDR $ABIO - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3321628-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3321628-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321651\" data-ts=\"1515427091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321651-goprominus-22-after-q4-forecast-cut-product-discount\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoPro -22% after Q4 forecast cut, product discount</a></h4><ul><li>        GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>) <a href=\"https://www.reuters.com/article/us-gopro-redundancies/gopro-lowers-sales-view-to-cut-over-250-jobs-after-weak-demand-idUSKBN1EX1DX?feedType=RSS&amp;feedName=technologyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtechnologyNews+%28Reuters+Technology+News%29\" target=\"_blank\">lowers</a> its Q4 revenue estimate to $340M from the prior $470M (+/- $10M) projection.</li><li>               The company lowers the price of its Hero6 cameras by $100 to $399 due to customer reluctance, which will have an $80M impact on the current quarter&rsquo;s revenue.&nbsp;</li><li>               Morgan Stanley says the price cut will make it difficult for GoPro to grow earnings in FY18.&nbsp;</li><li>GoPro shares are&nbsp;<font color='red'>down 22.1%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321334-job-cuts-gopros-aerial-division\" target=\"_blank\">Job cuts at GoPro's aerial division</a> (Jan. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321623-gopro-minus-4_3-percent-coo-svp-departures\" target=\"_blank\">GoPro -4.3% on COO, SVP departures</a> (Jan. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321651\" data-linked=\"GoPro -22% after Q4 forecast cut, product discount\" data-tweet=\"$GPRO - GoPro -22% after Q4 forecast cut, product discount https://seekingalpha.com/news/3321651-goprominus-22-after-q4-forecast-cut-product-discount?source=tweet\" data-url=\"https://seekingalpha.com/news/3321651-goprominus-22-after-q4-forecast-cut-product-discount\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321649\" data-ts=\"1515426999\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LAD\" target=\"_blank\">LAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321649-baml-warms-up-to-lithia-motors-and-sonic-automotive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML warms up to Lithia Motors and Sonic Automotive</a></h4><ul> <li>Lithia Motors (<a href='https://seekingalpha.com/symbol/LAD' title='Lithia Motors, Inc.'>LAD</a> <font color='green'>+2.3%</font>) and Sonic Automotive (<a href='https://seekingalpha.com/symbol/SAH' title='Sonic Automotive Inc.'>SAH</a> <font color='green'>+3%</font>) break higher after BAMNL <a href=\"https://www.streetinsider.com/Upgrades/BofAMerrill+Lynch+Upgrades+Sonic+Auto+%28SAH%29+to+Neutral%2C+Says+Valuation+Less+Compelling+Than+Other+Dealers/13664377.html\" target=\"_blank\">lifts</a> the auto retailers to Neutral from Underperform due to the impact of the new tax laws.</li> <li>Valuation on Lithia and Sonic still looks less compelling to BAML than on the pair's sector peers.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3321649\" data-linked=\"BAML warms up to Lithia Motors and Sonic Automotive\" data-tweet=\"$LAD $LAD $SAH - BAML warms up to Lithia Motors and Sonic Automotive https://seekingalpha.com/news/3321649-baml-warms-up-to-lithia-motors-and-sonic-automotive?source=tweet\" data-url=\"https://seekingalpha.com/news/3321649-baml-warms-up-to-lithia-motors-and-sonic-automotive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321648\" data-ts=\"1515426623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDIT\" target=\"_blank\">EDIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321648-editas-sees-three-candidates-in-early-stage-trials-2022\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Editas sees three candidates in early-stage trials by 2022</a></h4><ul><li>Editas Medicine (<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='red'>-17.2%</font>) <a href=\"https://seekingalpha.com/pr/17040351-editas-medicine-reports-recent-progress-announces-em22-five-year-goals-j-p-morgan-healthcare\" target=\"_blank\">updates </a>investors ahead of its Wednesday morning presentation at JPM18.</li><li>It expects to have three candidates in early-stage clinical development by 2022 (EM22) and two in or ready to enter late-stage development. The three will include two in ophthalmology and one from the collaboration with Juno Therapeutics (<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='red'>-1.6%</font>). The pipeline will also include at least one new kind of gene-edited cell therapeutic.</li><li>Leber Congenital Amaurosis type 10 (LCA10) IND filing on track for mid-year.</li><li>Two additional programs, recurrent ocular herpes simplex virus type 1 infection and Usher syndrome type 2a, are in preclinical testing.</li><li>Advancing engineered T cell receptor candidate for HPV-associated solid tumors with Juno.</li><li>Acquisition of i2 Pharma assets for guide RNA engineering and manufacturing should close this quarter.</li><li>#JPM18</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321632-crispr-cas9-gene-editing-firms-pressure-paper-questioning-potential-efficacy-cutting-element\" target=\"_blank\">CRISPR/Cas9 gene-editing firms under pressure on paper questioning potential efficacy of cutting element</a> (Jan. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321648\" data-linked=\"Editas sees three candidates in early-stage trials by 2022\" data-tweet=\"$EDIT $EDIT $JUNO - Editas sees three candidates in early-stage trials by 2022 https://seekingalpha.com/news/3321648-editas-sees-three-candidates-in-early-stage-trials-2022?source=tweet\" data-url=\"https://seekingalpha.com/news/3321648-editas-sees-three-candidates-in-early-stage-trials-2022\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321645\" data-ts=\"1515425802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFSI\" target=\"_blank\">PFSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321645-pennymac-financial-down-almost-4-bull-rings-register\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PennyMac Financial down almost 4% as bull rings the register</a></h4><ul><li>KBW's Bose George downgrades PennyMac Financial Services (<a href='https://seekingalpha.com/symbol/PFSI' title='PennyMac Financial Services'>PFSI</a> <font color='red'>-3.7%</font>) to Market Perform from Outperform. Prior to the downgrade, the stock had risen about 50% from its 2017 low.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321645\" data-linked=\"PennyMac Financial down almost 4% as bull rings the register\" data-tweet=\"$PFSI - PennyMac Financial down almost 4% as bull rings the register https://seekingalpha.com/news/3321645-pennymac-financial-down-almost-4-bull-rings-register?source=tweet\" data-url=\"https://seekingalpha.com/news/3321645-pennymac-financial-down-almost-4-bull-rings-register\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321644\" data-ts=\"1515425660\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321644-shire-to-run-business-two-divisions-investors-unmoved-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire to run business as two divisions; investors unmoved, shares down 4%</a></h4><ul><li>Shire plc (<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a> <font color='red'>-4.1%</font>) <a href=\"https://seekingalpha.com/pr/17040481-shire-announces-business-update-36th-annual-j-p-morgan-healthcare-conference\" target=\"_blank\">updates </a>investors on its business at JPMorgan's Healthcare Conference.</li><li>Company will operate as two divisions: Rare Disease and Neuroscience. Operating performance for each will reported beginning this quarter. Evaluation of strategic alternatives include potental independent listing of the two businesses.</li><li>Rare Diseases accounts for ~70% of the company's revenues.</li><li>15 programs in Phase 3 development. Total revenues to reach $17B - 18B by 2020.</li><li>Target non-GAAP net debt/EBITDA ratio less than 2.5 by year-end.</li><li>#JPM18</li></ul><div class=\"tiny-share-widget\" data-id=\"3321644\" data-linked=\"Shire to run business as two divisions; investors unmoved, shares down 4%\" data-tweet=\"$SHPG - Shire to run business as two divisions; investors unmoved, shares down 4% https://seekingalpha.com/news/3321644-shire-to-run-business-two-divisions-investors-unmoved-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3321644-shire-to-run-business-two-divisions-investors-unmoved-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321643\" data-ts=\"1515425410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STX\" target=\"_blank\">STX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321643-seagate-technologyplus-9_2-on-cryptocurrency-connection\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seagate Technology +9.2% on cryptocurrency connection</a></h4><ul><li>        Seagate Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a>) shares are&nbsp;<font color='green'>up 9.2%</font>&nbsp;after <a href=\"https://seekingalpha.com/article/4135878-seagate-technology-may-4-percent-ripple-credit-street\" target=\"_blank\">ValueStreet Research</a> outlines the company&rsquo;s investments in cryptocurrency.</li><li>        ValueStreet points to Crunchbase data showing that Seagate invested in the <a href=\"https://www.crunchbase.com/funding_round/ripple-labs-series-a--a32e5913\" target=\"_blank\">$28M Series A round</a> and <a href=\"https://www.crunchbase.com/funding_round/ripple-labs-series-b--d8515243\" target=\"_blank\">$55M Series B</a> round of Ripple, which owns 61% of cryptocurrency XRP.</li><li>               ValueStreet estimates that Seagate&rsquo;s Ripple investment, if current, could be worth $7.8B based on the fact that Ripple&rsquo;s XRP holdings are worth more than $160B.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317616-seagate-technology-will-cut-500-jobs\" target=\"_blank\">Seagate Technology will cut 500 jobs</a> (Dec. 11, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321643\" data-linked=\"Seagate Technology +9.2% on cryptocurrency connection\" data-tweet=\"$STX - Seagate Technology +9.2% on cryptocurrency connection https://seekingalpha.com/news/3321643-seagate-technologyplus-9_2-on-cryptocurrency-connection?source=tweet\" data-url=\"https://seekingalpha.com/news/3321643-seagate-technologyplus-9_2-on-cryptocurrency-connection\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321641\" data-ts=\"1515425393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCFT\" target=\"_blank\">HCFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321641-five-oaks-down-10-after-slashing-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Oaks down 10% after slashing dividend</a></h4><ul><li>The company after the close on Friday cut its monthly dividend by one-third to $0.333 per share. The annualized yield remains north of 10%.</li><li>OAKS&nbsp;<font color='red'>-9.9%</font>&nbsp;to $3.56, continuing a slide from the 2017 high of $5.61.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321509-five-oaks-investment-declares-0_0333-dividend\" target=\"_blank\">Five Oaks Investment declares $0.0333 dividend</a> (Jan. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321641\" data-linked=\"Five Oaks down 10% after slashing dividend\" data-tweet=\"$HCFT - Five Oaks down 10% after slashing dividend https://seekingalpha.com/news/3321641-five-oaks-down-10-after-slashing-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3321641-five-oaks-down-10-after-slashing-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321640\" data-ts=\"1515425303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTW\" target=\"_blank\">WTW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321640-weight-watchersplus-10-after-oprah-jolt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weight Watchers +10% after Oprah jolt</a></h4><ul><li>Weight Watchers (NYSE:<a href='https://seekingalpha.com/symbol/WTW' title='Weight Watchers International, Inc.'>WTW</a>) is&nbsp;<font color='green'>up 9.59%</font>&nbsp;on strong volume.</li><li>There hasn't been any company news announced today, but Weight Watchers stakeholder Oprah Winfrey is drawing some big headlines.</li><li>Oprah's Golden Globes speech last night received warm approval and some media outlets are reporting that she is \"actively thinking\" about running in the 2020 President election.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321640\" data-linked=\"Weight Watchers +10% after Oprah jolt\" data-tweet=\"$WTW $WW - Weight Watchers +10% after Oprah jolt https://seekingalpha.com/news/3321640-weight-watchersplus-10-after-oprah-jolt?source=tweet\" data-url=\"https://seekingalpha.com/news/3321640-weight-watchersplus-10-after-oprah-jolt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321638\" data-ts=\"1515424799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHTR\" target=\"_blank\">CHTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321638-charterplus-1_7-moffett-boosts-to-buy-citing-tax-benefits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Charter +1.7% as Moffett boosts to Buy, citing tax benefits</a></h4><ul>   <li>Charter Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a>) is <font color='green'>up 1.7%</font> after telecom analyst Craig Moffett boosted the stock to Buy with a substantial price target increase: to $436 from $350.</li>    <li>That target implies 24% upside from Friday's close. EPS should benefit from tax reform and capex deductions, Moffett notes, though the tax law changes also trim the value of the company's net operating losses. It's been a \"false narrative\" that the company won't benefit from tax reform.</li>    <li>Meanwhile, the shares have trimmed any M&amp;A premium they head after rumors of the company linking with several others had played out by the end of the year, he says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321638\" data-linked=\"Charter +1.7% as Moffett boosts to Buy, citing tax benefits\" data-tweet=\"$CHTR - Charter +1.7% as Moffett boosts to Buy, citing tax benefits https://seekingalpha.com/news/3321638-charterplus-1_7-moffett-boosts-to-buy-citing-tax-benefits?source=tweet\" data-url=\"https://seekingalpha.com/news/3321638-charterplus-1_7-moffett-boosts-to-buy-citing-tax-benefits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321637\" data-ts=\"1515424734\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/V\" target=\"_blank\">V</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321637-visa-expected-to-boost-employee-perks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Visa expected to boost employee perks</a></h4><ul> <li>Visa (<a href='https://seekingalpha.com/symbol/V' title='Visa Inc.'>V</a> <font color='green'>+0.4%</font>) will raise its 401K employee matching commitment and will examine making other long-term investments, according to <a href=\"https://twitter.com/CNBCnow/status/950384879153410049\" target=\"_blank\">CNBC</a>.</li> <li>The company is the latest major to boost employee benefits in front of what is likely to be some shareholder-friendly capital allocation moves.</li> <li>Shares of Visa had the third best return of the Dow constituents in 2017.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321637\" data-linked=\"Visa expected to boost employee perks\" data-tweet=\"$V - Visa expected to boost employee perks https://seekingalpha.com/news/3321637-visa-expected-to-boost-employee-perks?source=tweet\" data-url=\"https://seekingalpha.com/news/3321637-visa-expected-to-boost-employee-perks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321632\" data-ts=\"1515424282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDIT\" target=\"_blank\">EDIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321632-crispr-cas9-gene-editing-firms-under-pressure-on-paper-questioning-potential-efficacy-of\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CRISPR/Cas9 gene-editing firms under pressure on paper questioning potential efficacy of cutting element</a></h4><ul><li>Editas Medicine (<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='red'>-17.4%</font>), Intellia Therapeutics (<a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='red'>-18.5%</font>) and CRISPR Therapeutics (<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color='red'>-7.4%</font>) are down in early trading on the heels of a <a href=\"https://www.biorxiv.org/content/early/2018/01/05/243345\" target=\"_blank\">paper </a>published in the journal bioRxiv that questions the viability of the cutting element, the Cas9 enzyme, in the CRISPR/Cas9 gene-editing technology, due to the presence of anti-Cas9 antibodies.</li><li>An analysis of blood samples from ~24 people showed pre-existing adaptive immune responses to the widely-used versions of the Cas9 protein, derived from <em>Staphylococcus aureus</em> and <em>Streptococcus pyogenes</em>, both sources of frequent infections in humans.</li><li>The authors <a href=\"https://www.fiercebiotech.com/biotech/new-paper-could-put-crispr-biotechs-under-pressure\" target=\"_blank\">postulate </a>that patients' immune systems will react when exposed to Cas9 which could compromise the effectiveness of the genetic editing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321632\" data-linked=\"CRISPR/Cas9 gene-editing firms under pressure on paper questioning potential efficacy of cutting element\" data-tweet=\"$EDIT $EDIT $NTLA - CRISPR/Cas9 gene-editing firms under pressure on paper questioning potential efficacy of cutting element https://seekingalpha.com/news/3321632-crispr-cas9-gene-editing-firms-under-pressure-on-paper-questioning-potential-efficacy-of?source=tweet\" data-url=\"https://seekingalpha.com/news/3321632-crispr-cas9-gene-editing-firms-under-pressure-on-paper-questioning-potential-efficacy-of\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321635\" data-ts=\"1515424202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/H\" target=\"_blank\">H</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321635-hyatt-hotels-tracks-higher-after-raymond-james-nod\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hyatt Hotels tracks higher after Raymond James nod</a></h4><ul> <li>Raymond James <a href=\"https://www.benzinga.com/analyst-ratings/upgrades/18/01/11000858/benzingas-top-upgrades-downgrades-for-january-8-2018\" target=\"_blank\">upgrades</a> Hyatt Hotels (<a href='https://seekingalpha.com/symbol/H' title='Hyatt Hotels Corporation'>H</a> <font color='green'>+1.4%</font>) to an Outperform rating from Market Perform.</li> <li>The firm's price target on the hotel operator of $82 reps 12% upside potential.</li><li>Shares of Hyatt ran up a 33% gain in 2017 vs. +22% for the S&amp;P Lodging Index.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3321635\" data-linked=\"Hyatt Hotels tracks higher after Raymond James nod\" data-tweet=\"$H - Hyatt Hotels tracks higher after Raymond James nod https://seekingalpha.com/news/3321635-hyatt-hotels-tracks-higher-after-raymond-james-nod?source=tweet\" data-url=\"https://seekingalpha.com/news/3321635-hyatt-hotels-tracks-higher-after-raymond-james-nod\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321634\" data-ts=\"1515423678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321634-mellanox-technologies-largest-investor-slams-2018-targets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mellanox Technologies&#39; largest investor slams 2018 targets</a></h4><ul><li>Activist investor Starboard Value <a href=\"https://www.reuters.com/article/us-starboard-mellanox/starboard-says-chipmaker-mellanoxs-2018-targets-insufficient-idUSKBN1EX0YK?feedType=RSS&amp;feedName=technologyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtechnologyNews+%28Reuters+Technology+News%29\" target=\"_blank\">says</a> Mellanox Technologies&rsquo; (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) 2018 targets are &ldquo;not nearly enough&rdquo; and rely too much on revenue growth.</li><li>Starboard, the company's largest shareholder, made the comments in a letter to Mellanox.</li><li>Mellanox forecasts low to mid-teen percentage revenue growth this year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317901-mellanox-recoups-losses-new-positive-launch-susquehanna\" target=\"_blank\">Mellanox recoups some losses on New Positive launch at Susquehanna</a> (Dec. 12, 2017)</li><li>Mellanox shares are&nbsp;<font color='red'>down 1.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321634\" data-linked=\"Mellanox Technologies&#39; largest investor slams 2018 targets\" data-tweet=\"$MLNX - Mellanox Technologies&#39; largest investor slams 2018 targets https://seekingalpha.com/news/3321634-mellanox-technologies-largest-investor-slams-2018-targets?source=tweet\" data-url=\"https://seekingalpha.com/news/3321634-mellanox-technologies-largest-investor-slams-2018-targets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321631\" data-ts=\"1515423271\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321631-snapminus-4_7-jefferies-goes-to-hold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap -4.7% as Jefferies goes to Hold</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) is <font color='red'>4.5% lower</font> today after getting its second downgrade of the young new year, though it's also drawn a higher price target from one analyst who sees some budget positivity.</li>    <li>Last week, Cowen <a href=\"https://seekingalpha.com/news/3321115-snap-minus-2_9-percent-analyst-downgrade-price-target-reduction\" target=\"_blank\">cut Snap to Neutral</a> and trimmed its price target slightly. Now Jefferies has cut to Hold from Buy, noting the stock has hit their $15 price target and while they're still optimistic about the platform, it needs more fundamental execution (and Facebook is still the \"clear leader\" in social media).</li>    <li>Meanwhile, Credit Suisse has boosted its price target to $18 from $17, implying 30% upside from today's lower price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321631\" data-linked=\"Snap -4.7% as Jefferies goes to Hold\" data-tweet=\"$SNAP - Snap -4.7% as Jefferies goes to Hold https://seekingalpha.com/news/3321631-snapminus-4_7-jefferies-goes-to-hold?source=tweet\" data-url=\"https://seekingalpha.com/news/3321631-snapminus-4_7-jefferies-goes-to-hold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321623\" data-ts=\"1515421921\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321623-goprominus-4_3-on-coo-svp-departures\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoPro -4.3% on COO, SVP departures</a></h4><ul><li>        GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>) <a href=\"https://seekingalpha.com/filing/3825431\" target=\"_blank\">announces</a> that COO Charles Prober will leave the company effective February 16.</li><li>               SVP and General Counsel Sharon Zezima resigned from the company effective March 30.&nbsp;</li><li>               GoPro shares are&nbsp;<font color='red'>down 4.3%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321334-job-cuts-gopros-aerial-division\" target=\"_blank\">Job cuts at GoPro's aerial division</a> (Jan. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321623\" data-linked=\"GoPro -4.3% on COO, SVP departures\" data-tweet=\"$GPRO - GoPro -4.3% on COO, SVP departures https://seekingalpha.com/news/3321623-goprominus-4_3-on-coo-svp-departures?source=tweet\" data-url=\"https://seekingalpha.com/news/3321623-goprominus-4_3-on-coo-svp-departures\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321622\" data-ts=\"1515421750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321622-five-below-updates-guidance-ahead-of-icr-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Below updates guidance ahead of ICR talk</a></h4><ul>     <li>Five Below (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a>) is the latest company to update guidance ahead of its presentation at the ICR Conference.</li>     <li>The retailers announces that sales for the holiday period increased by 27% to $442.6M.</li>     <li>Comparable sales for the holiday period were up 6.7%.</li>     <li>\"We are pleased to share that our holiday sales performance was the strongest since our IPO in 2012,\" notes CEO Joel Anderson.</li>     <li>\"Given our strong quarter-to-date performance and expectations for the remainder of January, we expect to finish the fourth quarter and full year near the high end of our previously provided guidance ranges,\" he adds.</li>     <li>Q4 guidance: Sales of $491M to $503M, comparable sales increase of 4% to 6%, EPS of $1.09 to $1.16 vs. $1.17 consensus.</li>     <li>FY17 guidance: Sales of $1.264B to $1.276B, comparable sales increase of 5.7% to 6.5%, EPS of&nbsp;$1.72 to $1.79.</li>      <li>FIVE  <font color='red'>-2.58%</font> premarket to  $70.50.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/17040408-five-inc-announces-holiday-sales-results-quarter-date-january-6-2018-expects-fourth-quarter\" target=\"_blank\">Press Release</a></li><li><a href=\"https://seekingalpha.com/news/search?query=%23ICR18\" target=\"_blank\">#ICR18</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3321622\" data-linked=\"Five Below updates guidance ahead of ICR talk\" data-tweet=\"$FIVE - Five Below updates guidance ahead of ICR talk https://seekingalpha.com/news/3321622-five-below-updates-guidance-ahead-of-icr-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3321622-five-below-updates-guidance-ahead-of-icr-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321621\" data-ts=\"1515421678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXON\" target=\"_blank\">AXON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321621-axovants-lead-candidate-intepirdine-flunks-mid-stage-study-shares-down-48-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axovant&#39;s lead candidate intepirdine flunks mid-stage study; shares down 48% premarket</a></h4><ul><li>Axovant Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a>) craters&nbsp;<font color='red'>48%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17039815-axovant-announces-negative-results-intepirdine-phase-2b-headway-pilot-phase-2-gait-balance\" target=\"_blank\">announcement </a>that a Phase 2b clinical trial, HEADWAY, assessing lead candidate intepirdine in patients with Lewy body dementia &#40;LBD&#41;&nbsp;failed to demonstrate a treatment effect compared to placebo. The company says it will terminate development of the 5HT6 receptor antagonist.</li><li>On a positive note, an exploratory Phase 2 Visual Hallucination study evaluating nelotanserin in LBD and Parkinson's disease &#40;PD&#41;&nbsp;patients met its primary safety endpoint and demonstrated a treatment effect in the LBD group as measured by a scale called UPDRS Part III.</li><li>It failed to show a treatment effect, however, in another scale, SAPA-PD, in the entire population, but did so in a subset of PD patients with more severe symptoms. No improvements were observed in the full SAPS, PGIC-VH or in the patient diary.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321621\" data-linked=\"Axovant&#39;s lead candidate intepirdine flunks mid-stage study; shares down 48% premarket\" data-tweet=\"$AXON $AXON-OLD - Axovant&#39;s lead candidate intepirdine flunks mid-stage study; shares down 48% premarket https://seekingalpha.com/news/3321621-axovants-lead-candidate-intepirdine-flunks-mid-stage-study-shares-down-48-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3321621-axovants-lead-candidate-intepirdine-flunks-mid-stage-study-shares-down-48-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321620\" data-ts=\"1515421670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321620-pandoraminus-4_8-morgan-stanley-backs-off-bullishness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pandora -4.8% as Morgan Stanley backs off bullishness</a></h4><ul>   <li>Pandora Media (NYSE:<a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a>) is <font color='red'>4.8% lower</font> premarket after Morgan Stanley halved its price target, noting new challenges for the company in user engagement and monetization.</li>    <li>Analyst Benjamin Swinburne has downgraded to Equal Weight from Overweight and cut his formerly Street-high target to $6 from $12, reducing implied upside to 16% from a previous 132%.</li>    <li>Pandora's still up against free music on YouTube, not to mention new innovation from Apple, Spotify and Amazon.com, he says; the company has a \"less clear path\" toward meaningful free cash flow, with limited customer flexibility for accepting more ads even as music licensing costs continue to rise.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321620\" data-linked=\"Pandora -4.8% as Morgan Stanley backs off bullishness\" data-tweet=\"$P - Pandora -4.8% as Morgan Stanley backs off bullishness https://seekingalpha.com/news/3321620-pandoraminus-4_8-morgan-stanley-backs-off-bullishness?source=tweet\" data-url=\"https://seekingalpha.com/news/3321620-pandoraminus-4_8-morgan-stanley-backs-off-bullishness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321619\" data-ts=\"1515421291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321619-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/SPCB' title='SuperCom, Ltd.'>SPCB</a> <font color='green'>+62%</font>&nbsp;in process of <a href=\"https://seekingalpha.com/pr/17040363-supercom-develop-bitcoin-cryptocurrency-capabilities-mobile-money-suite-superpay\" target=\"_blank\">developing</a> various cryptocurrency capabilities for its SuperPay secure mobile money suite.</li><li><a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+46%</font>.</li><li><a href='https://seekingalpha.com/symbol/LITB' title='LightInTheBox Holding Co., Ltd.'>LITB</a> <font color='green'>+36%</font>&nbsp;on accepting bitcoin <a href=\"https://seekingalpha.com/pr/17039634-lightinthebox-accepts-bitcoin-payment\" target=\"_blank\">payment</a>.</li><li><a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='green'>+23%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17040222-oti-announces-cryptocurrency-acceptance-legitimate-source-purchase-payment\" target=\"_blank\">cryptocurrency</a> acceptance as a legitimate source of purchase payment.</li><li><a href='https://seekingalpha.com/symbol/ISIG' title='Insignia Systems, Inc.'>ISIG</a> <font color='green'>+16%</font>.</li><li><a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='green'>+16%</font>.</li><li><a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a> <font color='green'>+14%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17040232-agenus-inc-announces-230-million-royalty-monetization-healthcare-royalty-partners\" target=\"_blank\">announcement</a> of $230M non-dilutive royalty transaction with HealthCare Royalty Partners.</li><li><a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a> <font color='green'>+12%</font>.</li><li><a href='https://seekingalpha.com/symbol/ALDR' title='Alder Biopharmaceuticals Inc.'>ALDR</a> <font color='green'>+14%</font>&nbsp;as it goes to <a href=\"https://seekingalpha.com/news/3321610-alder-go-develop-commercialize-migraine-med-eptinezumab-settling-patent-dispute-teva-shares\" target=\"_blank\">develop</a> and commercialize migraine med eptinezumab after settling patent dispute with Teva.</li><li><a href='https://seekingalpha.com/symbol/MTNB' title='Matinas Biopharma Holdings, Inc.'>MTNB</a> <font color='green'>+10%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17039843-matinas-biopharma-achieves-statistical-endpoint-success-phase-2a-clinical-study-orally\" target=\"_blank\">positive</a> data from a third patient enrolled in the collaborative Phase 2a clinical study of Matinas&rsquo; lead anti-infective product candidate&nbsp;MAT2203.</li><li><a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='green'>+9%</font>&nbsp;on announced that consumers can now pre-order WattUp-enabled products with Myant&nbsp;SKIIN&nbsp;smart everyday apparel.</li><li><a href='https://seekingalpha.com/symbol/CERS' title='Cerus Corporation'>CERS</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17040174-cerus-corporation-announces-preliminary-product-revenue-results-fourth-quarter-full-year-2017\" target=\"_blank\">preliminary</a> product revenue.</li><li><a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/MZOR' title='Mazor Robotics Ltd.'>MZOR</a> <font color='green'>+8%</font>&nbsp;on revenue <a href=\"https://seekingalpha.com/news/3321555-mazor-robotics-expects-fy2017-revenue-65m-received-27-system-orders-q4\" target=\"_blank\">expectation</a>.</li><li><a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='green'>+7%</font>&nbsp;on guidance <a href=\"https://seekingalpha.com/news/3321570-kohls-pops-guidance-updates-icr\" target=\"_blank\">update</a>.</li><li><a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321619\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$SPCB $MYSZ $LITB - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3321619-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3321619-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321618\" data-ts=\"1515421176\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGEN\" target=\"_blank\">AGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321618-agenus-inks-230m-royalty-monetization-deal-shares-up-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agenus inks $230M royalty monetization deal; shares up 14% premarket</a></h4><ul><li>Agenus (NASDAQ:<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a>) is up&nbsp;<font color='green'>14%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17040232-agenus-inc-announces-230-million-royalty-monetization-healthcare-royalty-partners\" target=\"_blank\">monetization deal </a>with HealthCare Royalty Partners &#40;HCR&#41; for vaccine-related QS-21 royalties.</li><li>Under the terms of the transaction, Agenus will receive $230M, $190M in cash and $40M in milestones, in exchange for royalties on net sales of GlaxoSmithKline's (NYSE:<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>) QS-21-containing vaccines.</li><li>Agenus retains all rights to develop QS-21 with its internal lineup of checkpoint antibodies, vaccines and cellular therapies.</li><li>It will use a portion of the proceeds to redeem its royalty bond from Oberland and addition funds to advance studies of QS-21 with anti-CTLA-4 and anti-PD-1 therapies.</li><li>At closing, Agenus expects to have ~$28M after the Oberland transaction. It can also earn up to $40M in milestones, but will owe HCR ~$26M in 2021 if certain sales milestones are not met.</li><li>Glaxo's Shingrix shingles vaccine, approved in the U.S. in October 2017, contains Agenus' QS-21 adjuvant Stimulon.</li><li><strong>Update</strong>: On January 22, Agenus <a href=\"https://seekingalpha.com/pr/17051895-agenus-inc-closes-230-million-royalty-monetization-healthcare-royalty-partners\" target=\"_blank\">announced </a>that the deal closed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321618\" data-linked=\"Agenus inks $230M royalty monetization deal; shares up 14% premarket\" data-tweet=\"$AGEN $AGEN $GSK - Agenus inks $230M royalty monetization deal; shares up 14% premarket https://seekingalpha.com/news/3321618-agenus-inks-230m-royalty-monetization-deal-shares-up-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3321618-agenus-inks-230m-royalty-monetization-deal-shares-up-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321617\" data-ts=\"1515421071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMX\" target=\"_blank\">KMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321617-berenberg-positive-on-carmax\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Berenberg positive on CarMax</a></h4><ul> <li>Berenberg upgrades CarMax (NYSE:<a href='https://seekingalpha.com/symbol/KMX' title='CarMax Group'>KMX</a>) to a Buy rating after having the auto retailer set at Hold.</li> <li>The price target from the German firm of $83 reps 17% upside potential for shares.</li> <li>KMX <font color='green'>+1.01%</font> premarket to $71.76 vs. a 52-week trading range of $54.29 to $77.64.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321617\" data-linked=\"Berenberg positive on CarMax\" data-tweet=\"$KMX - Berenberg positive on CarMax https://seekingalpha.com/news/3321617-berenberg-positive-on-carmax?source=tweet\" data-url=\"https://seekingalpha.com/news/3321617-berenberg-positive-on-carmax\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321616\" data-ts=\"1515420887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321616-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='red'>-48%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17039815-axovant-announces-negative-results-intepirdine-phase-2b-headway-pilot-phase-2-gait-balance\" target=\"_blank\">announcing</a> negative results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies.</li><li><a href='https://seekingalpha.com/symbol/MFGP' title='Micro Focus International plc ADR'>MFGP</a>&nbsp;<font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3321585-micro-focus-international-reports-1h-results\" target=\"_blank\">announcing</a> 1H results.</li><li><a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color='red'>-11%</font>.</li><li><a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='red'>-11%</font>.</li><li><a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3321608-weak-guidance-sends-dave-and-busters-reeling\" target=\"_blank\">updating</a> guidance.</li><li><a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a> <font color='red'>-5%</font>.</li><li><a href='https://seekingalpha.com/symbol/CNIT-OLD' title='China Information Technology'>CNIT-OLD</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/RENN' title='Renren Inc.'>RENN</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/CNET' title='ChinaNet Online Holdings, Inc.'>CNET</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/APPN' title='Appian Corp.'>APPN</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17039723-dpw-holdings-makes-investment-sandstone-diagnostics\" target=\"_blank\">making</a> investment in Sandstone Diagnostics.</li><li><a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3321616\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$AXON-OLD $MFGP $CRSP - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3321616-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3321616-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321610\" data-ts=\"1515419934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDR\" target=\"_blank\">ALDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321610-alder-on-go-to-develop-and-commercialize-migraine-med-eptinezumab-after-settling-patent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alder on go to develop and commercialize migraine med eptinezumab after settling patent dispute with Teva; shares ahead 10% premarket</a></h4><ul><li>Alder BioPharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDR' title='Alder Biopharmaceuticals Inc.'>ALDR</a>) is up&nbsp;<font color='green'>10%&nbsp;</font>premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17040081-alder-biopharmaceuticals-enters-european-patent-settlement-global-license-agreement-teva\" target=\"_blank\">announcement</a> that has settled its patent dispute in Europe with Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) related to the latter's European patent covering calcitonin gene-related peptide &#40;CGRP&#41; antagonist antibodies. The action frees up Alder to develop, manufacture and commercialize lead candidate eptinezumab for migraine prevention under a non-exclusive global license (except Japan and Korea) to Teva's CGRP portfolio.</li><li>Under the terms of the agreement, Alder will withdraw its appeal before the European Patent Office and make an immediate $25M payment to Teva followed by a second $25M payment upon U.S. approval of eptinezumab or approval elsewhere in the licensed territory. Following commercial launch, Alder will pay Teva a $75M milestone if eptinezumab sales reach $1B, another $75M if sales reach $2B and royalties of 5 - 7%.</li><li>Concurrently, Alder has <a href=\"https://seekingalpha.com/pr/17040024-alder-announces-250-million-committed-equity-financing\" target=\"_blank\">secured </a>a private $250M capital raise with affiliates of Redmile Group LLC. Investors have agreed to purchase up to $250M of non-voting Class A Preferred Stock over a three-year period, including an initial investment of $100M. Net proceeds will fund the patent settlement and license agreement with Teva, eptinezumab commercialization preparations, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321610\" data-linked=\"Alder on go to develop and commercialize migraine med eptinezumab after settling patent dispute with Teva; shares ahead 10% premarket\" data-tweet=\"$ALDR $ALDR $TEVA - Alder on go to develop and commercialize migraine med eptinezumab after settling patent dispute with Teva; shares ahead 10% premarket https://seekingalpha.com/news/3321610-alder-on-go-to-develop-and-commercialize-migraine-med-eptinezumab-after-settling-patent?source=tweet\" data-url=\"https://seekingalpha.com/news/3321610-alder-on-go-to-develop-and-commercialize-migraine-med-eptinezumab-after-settling-patent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321608\" data-ts=\"1515419443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321608-weak-guidance-sends-dave-busters-reeling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weak guidance sends Dave &amp; Buster&#39;s reeling</a></h4><ul>     <li>Dave &amp; Buster's Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>) updates guidance ahead of its presentation at the iCR conference.</li>     <li>\"As indicated on our fiscal third quarter conference call, we had a slower-than-expected start to the fourth quarter. We expected sales to improve during our seasonally strong weeks in December but instead trends softened further leading us to update our financial outlook for fiscal year 2017,&rdquo; says CEO&nbsp;Steve King.</li>     <li>Comparable store sales at the chain were down 5.1% QTD through January 6.</li><li>The company expects FY17 revenue to be in the range of $1.138B to $1.142B vs. $1.148B&nbsp; to $1.155B prior view.</li><li>Comparable store sales for the full year are seen falling -1.0% to -0.7%, compared to prior guidance of 0.0% to 0.75%.</li>     <li>PLAY  <font color='red'>-9.53%</font> premarket to  $51.00.</li>          <li>Source: <a href=\"https://seekingalpha.com/pr/17040192-dave-and-buster-s-entertainment-inc-updates-fiscal-2017-guidance\" target=\"_blank\">Press Release</a></li><li><a href=\"https://seekingalpha.com/news/search?query=%23ICR18\" target=\"_blank\">#ICR18</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3321608\" data-linked=\"Weak guidance sends Dave &amp; Buster&#39;s reeling\" data-tweet=\"$PLAY - Weak guidance sends Dave &amp; Buster&#39;s reeling https://seekingalpha.com/news/3321608-weak-guidance-sends-dave-busters-reeling?source=tweet\" data-url=\"https://seekingalpha.com/news/3321608-weak-guidance-sends-dave-busters-reeling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321600\" data-ts=\"1515418318\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MFGP\" target=\"_blank\">MFGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321600-micro-focusminus-17-after-post-hpe-merger-interim-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micro Focus -17% after post-HPE merger interim results</a></h4><ul><li>        Micro Focus International (NYSE:<a href='https://seekingalpha.com/symbol/MFGP' title='Micro Focus International plc ADR'>MFGP</a>) announces its first interim results following merging its subsidiary with Seattle SpinCo, which has the software business of Hewlett Packard Enterprise.</li><li>               The six-month interim results include 1.23B in revenue, up 80% on the year. License revenue accounted for $327.7M (+121%), Maintenance for $611.5M (+68%), Subscription for $162.6M (+14%), Consultancy for $80.3M (+177%), and SaaS for $52.4M.</li><li>                  Other key financials: operating profit, $220M (+35%); adjusted EBITDA, $530.1M (+66%); adjusted diluted EPS, $1.039.    </li><li>                  Micro Focus shares are&nbsp;<font color='red'>down 17%</font>&nbsp;premarket.&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3321585-micro-focus-international-reports-1h-results\" target=\"_blank\">Micro Focus International reports 1H results</a> (Jan. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3321600\" data-linked=\"Micro Focus -17% after post-HPE merger interim results\" data-tweet=\"$MFGP - Micro Focus -17% after post-HPE merger interim results https://seekingalpha.com/news/3321600-micro-focusminus-17-after-post-hpe-merger-interim-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3321600-micro-focusminus-17-after-post-hpe-merger-interim-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321596\" data-ts=\"1515417622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321596-mimedx-reports-preliminary-2017-revenue-of-324_5m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx reports preliminary 2017 revenue of $324.5M</a></h4><ul><li>MiMedx Group (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a>) <a href=\"https://seekingalpha.com/pr/17039523-mimedx-releases-preliminary-2017-revenue-324_5-million-representing-32-percent-increase-2016\" target=\"_blank\">announces</a> preliminary Q4 and FY2017 revenue results and revenue expectations for Q1 2018.</li><li>The Company reported record revenue of $324.5M for FY2017 and $90.9M for Q4, representing a 32% and 30% increase over FY2016 and Q4 2016 respectively.</li><li>MiMedx reiterated its <a href=\"https://seekingalpha.com/news/3318022-mimedx-sees-revenues-high-387m-2018-shares-1-percent-premarket\" target=\"_blank\">previously</a> reported full year 2018 guidance.</li><li>The Company also provided an update to its Share Repurchase Program that was initiated in May 2014. The Company's Board of Directors has authorized $130M in share repurchases, since inception. To date, the amount of shares purchased is $124.2M.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321596\" data-linked=\"MiMedx reports preliminary 2017 revenue of $324.5M\" data-tweet=\"$MDXG - MiMedx reports preliminary 2017 revenue of $324.5M https://seekingalpha.com/news/3321596-mimedx-reports-preliminary-2017-revenue-of-324_5m?source=tweet\" data-url=\"https://seekingalpha.com/news/3321596-mimedx-reports-preliminary-2017-revenue-of-324_5m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321590\" data-ts=\"1515416806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WU\" target=\"_blank\">WU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321590-western-union-higher-again-amid-ripple-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Union higher again amid Ripple talk</a></h4><ul> <li>Western Union (NYSE:<a href='https://seekingalpha.com/symbol/WU' title='The Western Union Company'>WU</a>) breaks higher again on more talk that the company is working with Ripple on accepting its blockchain payment.</li> <li>Susquehanna lifts shares of WU to Neutral from Negative due in part to the Ripple potential.</li> <li>Shares of Western Union are <font color='green'>up 1.70%</font> premarket to $20.95.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321493-western-union-spikes-xrp-talk\" target=\"_blank\">Western Union spikes off of XRP talk</a> (Jan. 5)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3321590\" data-linked=\"Western Union higher again amid Ripple talk\" data-tweet=\"$WU - Western Union higher again amid Ripple talk https://seekingalpha.com/news/3321590-western-union-higher-again-amid-ripple-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3321590-western-union-higher-again-amid-ripple-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321583\" data-ts=\"1515416264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLK\" target=\"_blank\">SPLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321583-barclays-upgrades-splunk-ups-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays upgrades Splunk, ups price target</a></h4><ul><li>        Barclays <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=1&amp;ved=0ahUKEwjW0NnWs8jYAhVI_oMKHYbHB6sQqQIIJSgAMAA&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BComments%2FBarclays%2BUpgrades%2BSplunk%2B%2528SPLK%2529%2Bto%2BOverweight%2F13662305.html&amp;usg=AOvVaw1bFAV-jsVx1vbY6cxUXRfS\" target=\"_blank\">upgrades</a> Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) from Equal Weight to Overweight and raises the price target from $80 to $105, which is 18% above the current share price.</li><li>               Analyst Raimo Lenschow cites the potential for SIEM replacement cycle as a positive catalyst deserving estimate revisions.&nbsp;</li><li>               Splunk shares are&nbsp;<font color='green'>up 1.3%</font>&nbsp;premarket to $89.</li></ul><div class=\"tiny-share-widget\" data-id=\"3321583\" data-linked=\"Barclays upgrades Splunk, ups price target\" data-tweet=\"$SPLK - Barclays upgrades Splunk, ups price target https://seekingalpha.com/news/3321583-barclays-upgrades-splunk-ups-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3321583-barclays-upgrades-splunk-ups-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3321578\" data-ts=\"1515415587\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLIR\" target=\"_blank\">FLIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3321578-flir-begins-week-on-right-foot\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FLIR begins week on the right foot</a></h4><ul><li>FLIR Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/FLIR' title='FLIR Systems, Inc.'>FLIR</a>) <font color='green'>+1.1%</font> premarket after SunTrust <a href=\"https://stocknews.com/news/flir-suntrust-robinson-humphrey-raises-to-buy/\" target=\"_blank\">raised</a> the stock to Buy from Hold, with a price target of $55 (from $43).</li></ul><div class=\"tiny-share-widget\" data-id=\"3321578\" data-linked=\"FLIR begins week on the right foot\" data-tweet=\"$FLIR - FLIR begins week on the right foot https://seekingalpha.com/news/3321578-flir-begins-week-on-right-foot?source=tweet\" data-url=\"https://seekingalpha.com/news/3321578-flir-begins-week-on-right-foot\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}